[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2437
1. Link BK, Martin P, Kaminski MS, Goldsmith SJ, Coleman M, Leonard JP: Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. J Clin Oncol; 2010 Jun 20;28(18):3035-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study.
  • PURPOSE: The efficacy and safety of cyclophosphamide, vincristine, and prednisone (CVP) followed by tositumomab and iodine-131 ((131)I) -tositumomab therapy were evaluated in a multicenter phase II study in patients with untreated low-grade follicular lymphoma.
  • CONCLUSION: These mature data demonstrate that sequential therapy with a non-anthracycline-containing regimen comprising CVP followed by one cycle of tositumomab and (131)I-tositumomab produced high response rates with adequate safety and durable remissions and that this regimen represents a highly active treatment for first-line therapy of follicular non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / radiotherapy. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Radioimmunotherapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Feasibility Studies. Follow-Up Studies. Humans. Maximum Tolerated Dose. Middle Aged. Prednisone / administration & dosage. Remission Induction. Survival Rate. Time Factors. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20458031.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / iodine-131 anti-B1 antibody; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


2. Owen JS, Melhem M, Passarell JA, D'Andrea D, Darwish M, Kahl B: Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma. Cancer Chemother Pharmacol; 2010 Nov;66(6):1039-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma.
  • PURPOSE: The pharmacokinetic profiles of bendamustine and active metabolites were defined in patients with rituximab-refractory, relapsed indolent B-cell non-Hodgkin's lymphoma, and supported understanding of exposure-response relationships for efficacy and safety.

  • Hazardous Substances Data Bank. Bendamustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 May;59(6):759-70 [16957931.001]
  • [Cites] Nephron. 1976;16(1):31-41 [1244564.001]
  • [Cites] J Pharmacokinet Biopharm. 1981 Aug;9(4):503-12 [7310648.001]
  • [Cites] N Engl J Med. 1987 Oct 22;317(17):1098 [3657876.001]
  • [Cites] Anticancer Drugs. 1996 Jun;7(4):415-21 [8826610.001]
  • [Cites] Oncologist. 1999;4(3):191-6 [10394587.001]
  • [Cites] Anticancer Drugs. 2005 Sep;16(8):871-7 [16096436.001]
  • [Cites] Haematologica. 2005 Oct;90(10):1357-64 [16219572.001]
  • [Cites] Anticancer Drugs. 2007 Jun;18(5):587-95 [17414628.001]
  • [Cites] Br J Cancer. 2007 Jun 4;96(11):1692-8 [17486132.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):309-17 [18172283.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):204-10 [18182663.001]
  • [Cites] Cancer. 2010 Jan 1;116(1):106-14 [19890959.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Apr;132(4):205-12 [16402269.001]
  • [Cites] Lung Cancer. 2007 Jan;55(1):109-13 [17097191.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2096-105 [12357363.001]
  • (PMID = 20140617.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA014520-33; United States / NCI NIH HHS / CA / P30 CA014520-370005; United States / NCI NIH HHS / CA / CA014520-34S2; United States / NCI NIH HHS / CA / CA014520-27S29007; United States / NCI NIH HHS / CA / P30 CA014520-340003; United States / NCI NIH HHS / CA / P30 CA014520-339007; United States / NCI NIH HHS / CA / CA014520-360005; United States / NCI NIH HHS / CA / P30 CA014520-340001; United States / NCI NIH HHS / CA / CA014520-370004; United States / NCI NIH HHS / CA / P30 CA014520-27S29007; United States / NCI NIH HHS / CA / CA014520-289007; United States / NCI NIH HHS / CA / P30 CA014520-350004; United States / NCI NIH HHS / CA / P30 CA014520-360005; United States / NCI NIH HHS / CA / CA014520-299007; United States / NCI NIH HHS / CA / P30 CA014520-360004; United States / NCI NIH HHS / CA / CA014520-350001; None / None / / P30 CA014520-36; United States / NCI NIH HHS / CA / P30 CA014520-36; United States / NCI NIH HHS / CA / P30 CA014520-36S20004; United States / NCI NIH HHS / CA / P30 CA014520-36S1; United States / NCI NIH HHS / CA / CA014520-31S1; United States / NCI NIH HHS / CA / CA014520-36S20004; United States / NCI NIH HHS / CA / P30 CA014520-319007; United States / NCI NIH HHS / CA / P30 CA014520-33S1; United States / NCI NIH HHS / CA / P30 CA014520-32; United States / NCI NIH HHS / CA / CA014520-370005; None / None / / P30 CA014520-33; United States / NCI NIH HHS / CA / CA014520-340005; United States / NCI NIH HHS / CA / P30 CA014520-309007; United States / NCI NIH HHS / CA / CA014520-36S1; United States / NCI NIH HHS / CA / P30 CA014520-370004; United States / NCI NIH HHS / CA / P30 CA014520-32S1; United States / NCI NIH HHS / CA / P30 CA014520-340004; United States / NCI NIH HHS / CA / P30 CA014520-34; United States / NCI NIH HHS / CA / P30 CA014520; United States / NCI NIH HHS / CA / CA014520-350005; None / None / / P30 CA014520-32; United States / NCI NIH HHS / CA / CA014520-36S20003; United States / NCI NIH HHS / CA / CA014520-340003; United States / NCI NIH HHS / CA / CA014520-34S1; United States / NCI NIH HHS / CA / CA014520-339007; United States / NCI NIH HHS / CA / P30 CA014520-350003; United States / NCI NIH HHS / CA / P30 CA014520-35S1; United States / NCI NIH HHS / CA / CA014520-350004; United States / NCI NIH HHS / CA / P30 CA014520-360001; United States / NCI NIH HHS / CA / P30 CA014520-35; United States / NCI NIH HHS / CA / P30 CA014520-36S20005; United States / NCI NIH HHS / CA / P30 CA014520-38; United States / NCI NIH HHS / CA / P30 CA014520-33S2; United States / NCI NIH HHS / CA / P30 CA014520-370001; United States / NCI NIH HHS / CA / P30 CA014520-31; United States / NCI NIH HHS / CA / P30 CA014520-36S2; None / None / / P30 CA014520-30; United States / NCI NIH HHS / CA / CA014520-370001; United States / NCI NIH HHS / CA / CA014520-33S2; United States / NCI NIH HHS / CA / CA014520-360003; United States / NCI NIH HHS / CA / P30 CA014520-279007; United States / NCI NIH HHS / CA / P30 CA014520-31S1; United States / NCI NIH HHS / CA / P30 CA014520-360003; United States / NCI NIH HHS / CA / CA014520-32S1; United States / NCI NIH HHS / CA / CA014520-36S20001; United States / NCI NIH HHS / CA / P30 CA014520-340005; United States / NCI NIH HHS / CA / P30 CA014520-289007; United States / NCI NIH HHS / CA / CA014520-35S1; United States / NCI NIH HHS / CA / CA014520-340004; United States / NCI NIH HHS / CA / P30 CA014520-329007; United States / NCI NIH HHS / CA / CA014520-329007; None / None / / P30 CA014520-34; United States / NCI NIH HHS / CA / P30 CA014520-30; None / None / / P30 CA014520-31; United States / NCI NIH HHS / CA / P30 CA014520-370003; United States / NCI NIH HHS / CA / CA014520-279007; United States / NCI NIH HHS / CA / P30 CA014520-34S1; United States / NCI NIH HHS / CA / P30 CA014520-36S20003; United States / NCI NIH HHS / CA / CA014520-360004; United States / NCI NIH HHS / CA / CA014520-340001; United States / NCI NIH HHS / CA / P30 CA014520-37; United States / NCI NIH HHS / CA / CA014520-350003; United States / NCI NIH HHS / CA / CA014520-360001; United States / NCI NIH HHS / CA / P30 CA014520-299007; United States / NCI NIH HHS / CA / P30 CA014520-34S2; United States / NCI NIH HHS / CA / CA014520-319007; United States / NCI NIH HHS / CA / CA014520-269007; United States / NCI NIH HHS / CA / P30 CA014520-350005; United States / NCI NIH HHS / CA / P30 CA014520-36S20001; United States / NCI NIH HHS / CA / P30 CA014520-350001; None / None / / P30 CA014520-35; United States / NCI NIH HHS / CA / CA014520-370003; United States / NCI NIH HHS / CA / P30 CA014520-269007; United States / NCI NIH HHS / CA / CA014520-309007; United States / NCI NIH HHS / CA / CA014520-33S1; United States / NCI NIH HHS / CA / CA014520-36S2; United States / NCI NIH HHS / CA / CA014520-36S20005
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitrogen Mustard Compounds; 981Y8SX18M / Bendamustine Hydrochloride
  • [Other-IDs] NLM/ NIHMS213232; NLM/ PMC2956859
  •  go-up   go-down


3. Wang WL, Wen XP, Han L: [Clinical study of shenqi fuzheng injection and chemotherapy in CHOP protocol in treating malignant lymphoma]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2006 Jun;26(6):508-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study of shenqi fuzheng injection and chemotherapy in CHOP protocol in treating malignant lymphoma].
  • OBJECTIVE: To compare the efficacy and adverse reaction of chemotherapy in CHOP protocol (CT-CHOP) alone or compared with Shenqi Fuzheng injection (SFI) for treatment of moderate malignant non-Hodgkin's lymphoma.
  • CONCLUSION: Shenqi Fuzheng injection combined with CT-CHOP on malignant non-Hodgkin's lymphoma can reduce the adverse reaction of chemotherapy, ameliorate the compliance of patients to chemotherapy, and improve the immune function and QOL of patients.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16841665.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


Advertisement
4. Montella M, Maso LD, Crispo A, Talamini R, Bidoli E, Grimaldi M, Giudice A, Pinto A, Franceschi S: Do childhood diseases affect NHL and HL risk? A case-control study from northern and southern Italy. Leuk Res; 2006 Aug;30(8):917-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do childhood diseases affect NHL and HL risk? A case-control study from northern and southern Italy.
  • To investigate the association between non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), and exposure to childhood diseases, we analyzed an Italian case-control study that included 225 histologically-confirmed incident cases of NHL, 62 HL cases, and 504 controls.
  • Measles was negatively associated with NHL, particularly follicular B-cell NHL.
  • In addition, our study shows that measles may provide a protective effect against NHL.
  • [MeSH-major] Bacterial Infections / epidemiology. Chickenpox / epidemiology. Hodgkin Disease / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Paramyxoviridae Infections / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Causality. Female. Humans. Italy / epidemiology. Male. Middle Aged. Risk Factors

  • MedlinePlus Health Information. consumer health - Bacterial Infections.
  • MedlinePlus Health Information. consumer health - Chickenpox.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16406019.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


5. Heindl LM, Treutlein E, Jünemann AG, Kruse FE, Holbach LM: [Selective lacrimal sac biopsy for external dacryocystorhinostomy: a clinical pathological study]. Ophthalmologe; 2010 Dec;107(12):1139-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Lacrimal sac biopsy was performed in 19 external dacryocystorhinostomies (3.8%) including non-Hodgkin B-cell lymphoma (3), squamous carcinoma (2), mucoepidermoid carcinoma (1), malignant melanoma (1), oncocytoma (1), pyogenic granuloma (4), Wegener's granulomatosis (4) and sarcoidosis (3).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Tomography, Optical Coherence

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 2002 Jul;109 (7):1214-7; discussion 1217-8 [12093640.001]
  • [Cites] Ophthalmologe. 2008 Dec;105(12):1146-9 [18438631.001]
  • [Cites] Ophthalmology. 1986 Aug;93(8):1055-63 [3763155.001]
  • [Cites] Ophthalmologe. 1994 Jun;91(3):395-8 [8086760.001]
  • [Cites] Ophthalmology. 1997 Nov;104(11):1882-6 [9373121.001]
  • [Cites] Eye (Lond). 2003 Jul;17(5):599-606 [12855966.001]
  • [Cites] Ophthal Plast Reconstr Surg. 1992;8(4):237-42 [1476972.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2006 Mar-Apr;22(2):96-101 [16550051.001]
  • [Cites] Ophthalmologe. 2004 Jul;101(7):730-2 [15309490.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2003 May;19(3):173-6 [12918549.001]
  • [Cites] Am J Ophthalmol. 2005 Jun;139(6):1051-5 [15953435.001]
  • [Cites] Ophthal Plast Reconstr Surg. 1992;8(1):13-21 [1554647.001]
  • [Cites] Ophthalmology. 2001 Nov;108(11):2038-40 [11713075.001]
  • [Cites] Ophthal Plast Reconstr Surg. 1994 Sep;10 (3):169-84 [7947444.001]
  • [Cites] Br J Ophthalmol. 2005 Dec;89(12):1589-91 [16299137.001]
  • [Cites] Orbit. 2009;28(1):7-11 [19229737.001]
  • (PMID = 20535481.001).
  • [ISSN] 1433-0423
  • [Journal-full-title] Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
  • [ISO-abbreviation] Ophthalmologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


6. Mitrović Z, Radman I, Aurer I, Petranović D, Santek F, Labar B: [Primary central nervous system lymphoma--a single center experience]. Lijec Vjesn; 2007 Dec;129(12):391-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary central nervous system lymphoma--a single center experience].
  • Primary lymphoma of central nervous system (PCNSL) represents a distinct form of extranodal non-Hodgkin's lymphoma localized to central nervous system.
  • [MeSH-major] Central Nervous System Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18383741.001).
  • [ISSN] 0024-3477
  • [Journal-full-title] Lijec̆nic̆ki vjesnik
  • [ISO-abbreviation] Lijec Vjesn
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


7. Landgren O, Björkholm M, Montgomery SM, Hjalgrim H, Sjöberg J, Goldin LR, Askling J: Personal and family history of autoimmune diabetes mellitus and susceptibility to young-adult-onset Hodgkin lymphoma. Int J Cancer; 2006 Jan 15;118(2):449-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Personal and family history of autoimmune diabetes mellitus and susceptibility to young-adult-onset Hodgkin lymphoma.
  • Young-adult-onset (15-44 years of age) Hodgkin lymphoma (HL) is believed to arise as a consequence of late primary infection in susceptible individuals.
  • Cases with young-adult-onset HL were less likely to have a personal (OR =0.5, 95% CI 0.2-1.1) or family (OR =0.7, 95% CI 0.6-0.8) history of diabetes mellitus.
  • These findings suggests that characteristics of the immune system associated with conditions such as diabetes mellitus type I are of importance in the pathogenesis of young-adult-onset HL.
  • [MeSH-major] Diabetes Mellitus, Type 1 / complications. Diabetes Mellitus, Type 1 / genetics. Hodgkin Disease / etiology
  • [MeSH-minor] Adult. Age of Onset. Case-Control Studies. Female. Humans. Immune System / physiology. Male. Middle Aged. Odds Ratio. Pedigree. Risk Factors


8. Biagi JJ, Herbert KE, Smith C, Abdi E, Leahy M, Falkson C, Wolf M, Januszewicz H, Seymour JF, Richards K, Matthews JP, Dale B, Prince HM: A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma. Leuk Lymphoma; 2005 Feb;46(2):197-206
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma.
  • The 4-day combination of dexamethasone, ifosfamide, cisplatin, and etoposide (DICE) is a salvage regimen for lymphoma.
  • We report a prospective phase II multi-center trial of a modified DICE regimen in relapsed or refractory Hodgkin (HL) or non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), constituting a single day of intravenous administration followed by 3 days of oral administration, aimed at reducing inpatient days without losing efficacy.
  • Forty patients (median age 56, range 25 - 79) were included: 28 (70%) NHL, 9 (23%) HL and 3 (8%) CLL.
  • International Prognostic Index (IPI) was 2 in 75% of NHL patients.
  • OS was longer in the < 55 compared to the 55 age cohort (P = 0.0091), longer for HL than NHL (P = 0.59 and 0.039 respectively) and longer for Low/Low-Int IPI than High/High-Int IPI (P = 0.0074 and 0.0009 respectively).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Dexamethasone / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Remission Induction. Survival Analysis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621802.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


9. Hauswirth AW, Skrabs C, Schützinger C, Raderer M, Chott A, Valent P, Lechner K, Jäger U: Autoimmune thrombocytopenia in non-Hodgkin's lymphomas. Haematologica; 2008 Mar;93(3):447-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autoimmune thrombocytopenia in non-Hodgkin's lymphomas.
  • Autoimmune thrombocytopenia is a common immunehematologic complication in non-Hodgkin's lymphomas and may complicate the treatment.
  • We analyzed an original series from our institute as well as published cases of non-Hodgkin's lymphomas (excluding chronic lymphocytic leukemia) associated with autoimmune thrombocytopenia with regard to demographic factors, prevalence in non-Hodgkin's lymphoma subtypes and treatment outcome.
  • Half of the cases occurred prior to diagnosis of lymphoma.
  • Chemotherapy is the best treatment in many non-Hodgkin's lymphomas patients with autoimmune thrombocytopenia compared with standard treatment of autoimmune thrombocytopenia.
  • Splenectomy is effective in splenic marginal zone lymphoma.
  • Autoimmune thrombocytopenia in patients with non-Hodgkin's lymphomas is potentially life-threatening and difficult to treat.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Purpura, Thrombocytopenic, Idiopathic / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Child. Combined Modality Therapy. Comorbidity. Female. Humans. Leukemia, Hairy Cell / drug therapy. Leukemia, Hairy Cell / epidemiology. Male. Middle Aged. Multiple Myeloma / epidemiology. Peripheral Blood Stem Cell Transplantation. Postoperative Complications / epidemiology. Prevalence. Splenectomy. Treatment Outcome. Waldenstrom Macroglobulinemia / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18287133.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


10. Stephens M: The lived experience post-autologous haematopoietic stem cell transplant (HSCT): a phenomenological study. Eur J Oncol Nurs; 2005 Sep;9(3):204-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five adult patients who had previously undergone autologous transplantation for a haematological malignancy at least 6 months before participated in the study.
  • [MeSH-minor] Activities of Daily Living. Adult. Cost of Illness. Family / psychology. Fear. Female. Grief. Humans. Leukemia / therapy. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Multiple Myeloma / therapy. Nursing Methodology Research. Qualitative Research. Quality of Life. Social Isolation. Social Support. Surveys and Questionnaires. Transplantation, Autologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Oncol Nurs. 2005 Sep;9(3):202-3 [16048745.001]
  • [CommentIn] Eur J Oncol Nurs. 2005 Sep;9(3):216-7 [16085460.001]
  • (PMID = 16112523.001).
  • [ISSN] 1462-3889
  • [Journal-full-title] European journal of oncology nursing : the official journal of European Oncology Nursing Society
  • [ISO-abbreviation] Eur J Oncol Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  •  go-up   go-down


11. Löfström B, Backlin C, Sundström C, Ekbom A, Lundberg IE: A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study. Ann Rheum Dis; 2007 Dec;66(12):1627-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study.
  • OBJECTIVE: To investigate risk factors for non-Hodgkin's lymphoma (NHL) and analyse NHL subtypes and characteristics in patients with systemic lupus erythematosus (SLE).
  • A nested case control study on SLE patients who developed NHL during this observation period was performed with SLE patients without malignancy as controls.
  • Tissue specimens on which the lymphoma diagnosis was based were retrieved and reclassified according to the WHO classification.
  • NHLs of the subtype diffuse large B cell lymphoma (DLBCL) were subject to additional immunohistochemical staining using antibodies against bcl-6, CD10 and IRF-4 for further subclassification into germinal centre (GC) or non-GC subtypes.
  • RESULTS: 16 patients with SLE had NHL, and the DLBCL subtype dominated (10 cases).
  • The 5-year overall survival and mean age at NHL diagnosis were comparable with NHL in the general population-50% and 61 years, respectively.
  • Cyclophosphamide or azathioprine use did not elevate lymphoma risk, but the risk was elevated if haematological or sicca symptoms, or pulmonary involvement was present in the SLE disease.
  • CONCLUSIONS: NHL in this national SLE cohort was predominated by the aggressive DLBCL subtype.
  • The prognosis of NHL was comparable with that of the general lymphoma population.
  • [MeSH-major] Lupus Erythematosus, Systemic / complications. Lymphoma, Non-Hodgkin / complications
  • [MeSH-minor] Adult. Aged. Antigens, Viral / analysis. Case-Control Studies. Confidence Intervals. Female. Herpesvirus 4, Human / immunology. Humans. Immunohistochemistry. In Situ Hybridization. Lymphoma, Large B-Cell, Diffuse / classification. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / virology. Male. Middle Aged. Risk Assessment. Survival Analysis. Sweden

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Systemic lupus erythematosus.
  • MedlinePlus Health Information. consumer health - Lupus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Semin Arthritis Rheum. 2007 Feb;36(4):246-55 [16996579.001]
  • [Cites] Rheumatology (Oxford). 2000 Oct;39(10):1147-52 [11035137.001]
  • [Cites] Lupus. 2001;10(6):394-400 [11434573.001]
  • [Cites] Lupus. 2001;10(7):500-4 [11480849.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1136-43 [11830458.001]
  • [Cites] Br J Dermatol. 2002 May;146(5):877-81 [12000388.001]
  • [Cites] Ann Rheum Dis. 2002 Jun;61(6):554-8 [12006334.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Scand J Rheumatol. 2002;31(2):66-71 [12109649.001]
  • [Cites] Curr Rheumatol Rep. 2002 Aug;4(4):351-8 [12126588.001]
  • [Cites] Blood. 2003 Jan 1;101(1):78-84 [12393466.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):722-8 [12576441.001]
  • [Cites] Arthritis Rheum. 2003 Jun;48(6):1543-50 [12794821.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):464-70 [15087665.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Ann Intern Med. 1978 Dec;89(6):888-92 [102228.001]
  • [Cites] J Chronic Dis. 1978;31(11):691-6 [730824.001]
  • [Cites] Ann Rheum Dis. 1992 Apr;51(4):437-9 [1586239.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Lakartidningen. 1994 Feb 16;91(7):598, 603-5 [8114596.001]
  • [Cites] Arthritis Rheum. 1996 Jun;39(6):1050-4 [8651970.001]
  • [Cites] Arthritis Rheum. 1997 Apr;40(4):761-8 [9125261.001]
  • [Cites] Arthritis Rheum. 1997 Sep;40(9):1725 [9324032.001]
  • [Cites] BMJ. 1998 Jul 18;317(7152):180-1 [9665898.001]
  • [Cites] Arthritis Rheum. 2005 May;52(5):1481-90 [15880596.001]
  • [Cites] Mod Pathol. 2005 Aug;18(8):1113-20 [15920553.001]
  • [Cites] Ann Rheum Dis. 2005 Oct;64(10):1507-9 [16162903.001]
  • [Cites] Arthritis Rheum. 2006 Mar;54(3):692-701 [16508929.001]
  • [Cites] Ann Rheum Dis. 2006 Jun;65(6):796-803 [16284097.001]
  • [Cites] J Rheumatol. 2000 Mar;27(3):685-91 [10743809.001]
  • (PMID = 17517757.001).
  • [ISSN] 1468-2060
  • [Journal-full-title] Annals of the rheumatic diseases
  • [ISO-abbreviation] Ann. Rheum. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Viral
  • [Other-IDs] NLM/ PMC2095297
  •  go-up   go-down


12. Bishop MR, Dean RM, Steinberg SM, Odom J, Pollack SM, Pavletic SZ, Sportes C, Gress RE, Fowler DH: Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma. Cancer; 2010 Feb 15;116(4):852-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.
  • BACKGROUND: Chemotherapy sensitivity, defined simply as at least a partial response to chemotherapy, is an important outcome predictor for non-Hodgkin lymphoma (NHL) patients undergoing reduced-intensity allogeneic hematopoietic stem cell transplantation (allo-HCT).
  • METHODS: The impact of pretransplant and early (28 days) post-transplant disease response on transplant outcomes was analyzed in 63 NHL patients treated with reduced-intensity allo-HCT.
  • CONCLUSIONS: These data suggest that NHL patients with pretransplant SD, generally considered inappropriate candidates, may benefit from reduced-intensity allo-HCT, and patients with pretransplant PD should only receive this therapy in clinical trials.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Non-Hodgkin / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Male. Middle Aged. Postoperative Period. Prednisone / therapeutic use. Preoperative Period. Survival Rate. Transplantation Conditioning. Transplantation, Autologous. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20041482.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; EPOCH protocol
  •  go-up   go-down


13. Alston RD, Geraci M, Eden TO, Moran A, Rowan S, Birch JM: Changes in cancer incidence in teenagers and young adults (ages 13 to 24 years) in England 1979-2003. Cancer; 2008 Nov 15;113(10):2807-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The increase in non-Hodgkin lymphoma was greater in individuals ages 20 to 24 year than in younger individuals, but the increase in Hodgkin lymphoma was confined to individuals ages 13 to 14 years.
  • [MeSH-minor] Adolescent. Age Distribution. England / epidemiology. Female. Humans. Incidence. Male. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18846564.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. Lopes da Silva R, Fernandes T, Lopes A, Santos S, Mafra M, Rodrigues AS, de Sousa AB: B lymphoblastic lymphoma presenting as a tumor of the nasopharynx in an adult patient. Head Neck Pathol; 2010 Dec;4(4):318-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B lymphoblastic lymphoma presenting as a tumor of the nasopharynx in an adult patient.
  • In adults, non-Hodgkin's lymphoma (NHL) is the second most common neoplasm found in the head and neck region after squamous cell carcinoma.
  • Within this region, primary NHL of the nasopharynx is rare.
  • We report the case of a 28-year-old male diagnosed with a B lymphoblastic lymphoma (CD20-; CD79a+; CD3-; CD10+; PAX5+, CyclinD1-; TdT+) of the nasopharynx extending to the deep and superficial structures of the right hemiface, to the skull base with an intracranial component and a small but detectable bone marrow involvement, who was started on chemotherapy with a complete response.
  • To the best of our knowledge, this is the first case of a primary nasopharynx B-LBL in an adult patient with such aggressive regional spread to be reported in the literature.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adult. Biopsy. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology. Male. Remission Induction

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rinsho Ketsueki. 1999 Nov;40(11):1193-7 [10624131.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] Am J Surg Pathol. 2000 Nov;24(11):1480-90 [11075849.001]
  • [Cites] Am J Clin Pathol. 2001 Jun;115(6):868-75 [11392884.001]
  • [Cites] Head Neck. 2001 Jul;23(7):547-58 [11400243.001]
  • [Cites] Leuk Lymphoma. 2001 Sep-Oct;42(5):1005-13 [11697617.001]
  • [Cites] Chin Med J (Engl). 2000 Feb;113(2):148-50 [11775540.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2220-4 [14576732.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1624-30 [15178574.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2004 Jul;26(7):425-9 [15355649.001]
  • [Cites] Am J Clin Pathol. 1983 Mar;79(3):387-91 [6338702.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):768-76 [4016670.001]
  • [Cites] Laryngoscope. 1987 Mar;97(3 Pt 1):291-300 [3821348.001]
  • [Cites] Am J Surg Pathol. 1987 Jun;11(6):418-29 [3496014.001]
  • [Cites] AJR Am J Roentgenol. 1987 Oct;149(4):785-91 [3498332.001]
  • [Cites] J Clin Oncol. 1989 Sep;7(9):1275-80 [2769328.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1190-7 [2205355.001]
  • [Cites] Strahlenther Onkol. 1996 Jul;172(7):356-66; discussion 367-8 [8693402.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Jan;32B(1):19-23 [8729614.001]
  • [Cites] Leuk Lymphoma. 1996 Nov;23(5-6):577-82 [9031089.001]
  • [Cites] No Shinkei Geka. 2005 Nov;33(11):1107-11 [16277225.001]
  • [Cites] J Egypt Natl Canc Inst. 2005 Mar;17(1):15-9 [16353078.001]
  • [Cites] J Cutan Pathol. 2006 Sep;33(9):649-53 [16965342.001]
  • [Cites] Leuk Lymphoma. 2006 Oct;47(10):2132-9 [17071487.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jun;103(6):814-9 [17531941.001]
  • [Cites] Ann Hematol. 2008 Aug;87(8):677-9 [18365194.001]
  • [Cites] Arch Dermatol. 2008 Sep;144(9):1155-62 [18794461.001]
  • [Cites] Ann Hematol. 2009 May;88(5):441-7 [18931844.001]
  • (PMID = 20730608.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2996508
  •  go-up   go-down


15. Shiels MS, Cole SR, Wegner S, Armenian H, Chmiel JS, Ganesan A, Marconi VC, Martinez-Maza O, Martinson J, Weintrob A, Jacobson LP, Crum-Cianflone NF: Effect of HAART on incident cancer and noncancer AIDS events among male HIV seroconverters. J Acquir Immune Defic Syndr; 2008 Aug 1;48(4):485-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: Prospective cohort study using 2,121 HIV+ male seroconverters (median age: 28 years, 51% white/non-Hispanic) in the Tri-Service AIDS Clinical Consortium (n = 1694) and the Multicenter AIDS Cohort Study (n = 427).
  • RESULTS: Eighty-one AIDS-defining cancers (64 Kaposi sarcomas; 17 non-Hodgkin lymphomas) and 343 other AIDS events occurred during 14,483 person-years in 1990-2006.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Epidemiol. 2002 Oct;31(5):951-8 [12435766.001]
  • [Cites] Epidemiology. 2000 Sep;11(5):550-60 [10955408.001]
  • [Cites] Lancet. 2003 Jul 5;362(9377):22-9 [12853195.001]
  • [Cites] Am J Epidemiol. 2003 Oct 1;158(7):687-94 [14507605.001]
  • [Cites] Lancet. 2003 Oct 18;362(9392):1267-74 [14575971.001]
  • [Cites] Comput Methods Programs Biomed. 2004 Jul;75(1):45-9 [15158046.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85 [15220706.001]
  • [Cites] J Natl Cancer Inst. 2004 Jul 21;96(14):1070-6 [15265968.001]
  • [Cites] Clin Infect Dis. 2004 Nov 1;39(9):1380-4 [15494916.001]
  • [Cites] Biometrics. 1986 Mar;42(1):121-30 [3719049.001]
  • [Cites] Am J Epidemiol. 1987 Aug;126(2):310-8 [3300281.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] Stat Med. 1994 Oct 15-30;13(19-20):2127-39 [7846415.001]
  • [Cites] Biometrics. 1995 Jun;51(2):524-32 [7662841.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Sep 1;22(1):65-70 [10534148.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] Am J Epidemiol. 2000 Nov 15;152(10):923-33 [11092434.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] AIDS. 2001 Feb 16;15(3):347-55 [11273215.001]
  • [Cites] J Infect. 2001 Feb;42(2):134-9 [11531320.001]
  • [Cites] Am J Epidemiol. 2001 Oct 1;154(7):675-81 [11581102.001]
  • [Cites] J Epidemiol Community Health. 2002 Feb;56(2):153-9 [11812817.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 May 1;30(1):81-7 [12048367.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 May 1;30(1):111-8 [12048371.001]
  • [Cites] N Engl J Med. 1997 Sep 11;337(11):725-33 [9287227.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):543-9 [9492772.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] JAMA. 1998 Nov 4;280(17):1497-503 [9809730.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S34-41 [10430217.001]
  • [Cites] AIDS. 1999 Oct 1;13(14):1933-42 [10513653.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] Lancet. 2005 Jul 30-Aug 5;366(9483):378-84 [16054937.001]
  • [Cites] AIDS. 2005 Nov 18;19(17):2009-18 [16260908.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):194-200 [16394852.001]
  • [Cites] Am J Epidemiol. 2006 Feb 15;163(4):310-5 [16371516.001]
  • [Cites] AIDS. 2006 Jul 13;20(11):1531-8 [16847408.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] HIV Med. 2006 Sep;7(6):369-77 [16903981.001]
  • [Cites] Stat Med. 2007 May 20;26(11):2389-430 [17031868.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):142-4 [12455069.001]
  • (PMID = 18614916.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI035042-11; United States / NIAID NIH HHS / AI / HU0001-05-2-0011; United States / NIAID NIH HHS / AI / AI035041-10; United States / NIAID NIH HHS / AI / U01 AI035042; United States / NIAID NIH HHS / AI / U01 AI037984; United States / NIDDK NIH HHS / DK / U01 DK066116; United States / NIAID NIH HHS / AI / AI035039-16; United States / NIAID NIH HHS / AI / UO1-AI-35042; United States / NIAID NIH HHS / AI / U01 AI035041-17; United States / NIAID NIH HHS / AI / UO1-AI-37984; United States / NIAID NIH HHS / AI / U01 AI035040-16; United States / NCI NIH HHS / CA / T32 CA009314-27S1; United States / NIAID NIH HHS / AI / UO1-AI-35040; United States / NIAID NIH HHS / AI / U01 AI035039-17; United States / NIAID NIH HHS / AI / AI037984-08; United States / NIAID NIH HHS / AI / U01 AI035043-11; United States / NIAID NIH HHS / AI / AI035039-17; United States / NIAID NIH HHS / AI / AI035043-10; United States / NIAID NIH HHS / AI / U01 AI035042-17; United States / NIAID NIH HHS / AI / U01 AI037613; United States / NIAID NIH HHS / AI / U01 AI037613-08; United States / NIAID NIH HHS / AI / UO1-AI-35041; United States / NCRR NIH HHS / RR / M01 RR000722; United States / NIAID NIH HHS / AI / U01 AI035041; United States / NIAID NIH HHS / AI / AI035042-17; United States / NIAID NIH HHS / AI / UM1 AI035043; United States / NIAID NIH HHS / AI / U01 AI037984-08; United States / NCI NIH HHS / CA / T32 CA009314-28S3; United States / PHS HHS / / HU0001-05-2-0011; None / None / / M01 RR000722-23; United States / NCI NIH HHS / CA / CA009314-26S1; United States / NIAID NIH HHS / AI / U01 AI035039-16; United States / NIAID NIH HHS / AI / U01 AI035043; United States / NIAID NIH HHS / AI / UO1-AI-35039; United States / NIAID NIH HHS / AI / AI037613-08; United States / NIAID NIH HHS / AI / U01 AI035041-10; United States / NIAID NIH HHS / AI / U01 AI035040; United States / NCRR NIH HHS / RR / 5-MO1-RR-00722; United States / NCRR NIH HHS / RR / M01 RR000722-23; United States / NIAID NIH HHS / AI / U01 AI035043-10; United States / NCI NIH HHS / CA / T32 CA009314-26S1; United States / NCI NIH HHS / CA / CA009314-28S3; United States / NIAID NIH HHS / AI / U01 AI035039; United States / NIAID NIH HHS / AI / UO1-AI-35043; United States / NIAID NIH HHS / AI / UO1-AI-37613; United States / NCI NIH HHS / CA / T32 CA009314
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  • [Other-IDs] NLM/ NIHMS165363; NLM/ PMC2805176
  •  go-up   go-down


16. Han B, Yang Z, Yang T, Gao W, Sang X, Zhao Y, Shen T: Diagnostic splenectomy in patients with fever of unknown origin and splenomegaly. Acta Haematol; 2008;119(2):83-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Histologic findings included 29 cases of non-Hodgkin lymphoma, 4 cases of spleen tuberculosis, 3 cases of Hodgkin lymphoma, 1 case of Castleman disease and 2 cases of hemophagocytic syndrome.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Lymphoma / complications. Lymphoma / diagnosis. Male. Middle Aged. Postoperative Complications. Retrospective Studies. Risk Factors. Survival Rate

  • Genetic Alliance. consumer health - Splenomegaly.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel
  • (PMID = 18305380.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


17. Berrington de González A, Urban MI, Sitas F, Blackburn N, Hale M, Patel M, Ruff P, Sur R, Newton R, Beral V: Antibodies against six human herpesviruses in relation to seven cancers in black South Africans: a case control study. Infect Agent Cancer; 2006;1:2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For example, Epstein-Barr Virus is considered a cause of Burkitt's lymphoma and other immunosuppression related lymphomas, Hodgkin lymphoma, and nasopharyngeal cancer.
  • METHODS: We conducted a systematic sub-study from within an ongoing case control study of adult black South Africans to investigate the relationship between antibodies to six human herpesviruses and seven cancer groups that may be caused by infectious agents.
  • Subjects had incident cancers of the oral cavity (n = 88), the cervix (n = 53), the prostate (n = 66), Hodgkin lymphoma (n = 83), non-Hodgkin lymphoma (n = 80), multiple myeloma (n = 94) or leukaemia (n = 203).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1996 Mar 1;65(5):584-90 [8598307.001]
  • [Cites] J Med Virol. 1994 Mar;42(3):224-7 [7911825.001]
  • [Cites] Ann Epidemiol. 1995 Nov;5(6):497-500 [8680614.001]
  • [Cites] Eur J Cancer Prev. 1998 Jun;7(3):201-6 [9696928.001]
  • [Cites] J Infect Dis. 1998 Sep;178(3):846-9 [9728556.001]
  • [Cites] Br J Cancer. 1999 Jun;80(7):1103-6 [10362124.001]
  • [Cites] N Engl J Med. 1999 Jun 17;340(24):1863-71 [10369849.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):489-92 [11054682.001]
  • [Cites] Epidemiol Rev. 2001;23(1):144-51 [11588840.001]
  • [Cites] Leukemia. 2002 Apr;16(4):716-9 [11960354.001]
  • [Cites] J Natl Cancer Inst. 2002 Nov 6;94(21):1604-13 [12419786.001]
  • [Cites] J Exp Pathol. 1992;6(1-2):95-105 [1320669.001]
  • [Cites] Leukemia. 1992 Nov;6(11):1229-31 [1331626.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):753-5 [15728806.001]
  • [Cites] Microbiol Immunol. 1991;35(11):1023-7 [1663574.001]
  • [Cites] Nature. 1978 Aug 24;274(5673):756-61 [210392.001]
  • [Cites] Int J Cancer. 1990 May 15;45(5):829-33 [2159435.001]
  • [Cites] Eur J Cancer. 1995;31A(9):1479-86 [7577076.001]
  • [Cites] N Engl J Med. 1996 Jul 25;335(4):233-41 [8657239.001]
  • (PMID = 17150131.001).
  • [ISSN] 1750-9378
  • [Journal-full-title] Infectious agents and cancer
  • [ISO-abbreviation] Infect. Agents Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1635002
  •  go-up   go-down


18. Hardell L, Eriksson M, Carlberg M, Sundström C, Mild KH: Use of cellular or cordless telephones and the risk for non-Hodgkin's lymphoma. Int Arch Occup Environ Health; 2005 Sep;78(8):625-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of cellular or cordless telephones and the risk for non-Hodgkin's lymphoma.
  • OBJECTIVES: To evaluate the use of cellular and cordless telephones as the risk factor for non-Hodgkin's lymphoma (NHL).
  • NHL of the B-cell type was not associated with the use of cellular or cordless telephones.
  • Regarding T-cell NHL and >5 year latency period, the use of analogue cellular phones yielded: odds ratio (OR) = 1.46, 95%; confidence interval (CI) = 0.58-3.70, digital: OR=1.92, 95%; CI=0.77-4.80 and cordless phones: OR=2.47; CI=1.09-5.60.
  • The corresponding results for certain, e.g. cutaneous and leukaemia, T-cell lymphoma for analogue phones were: OR=3.41, 95%; CI=0.78-15.0, digital: OR=6.12, 95%; CI=1.26-29.7 and cordless phones: OR=5.48, 95%; CI=1.26-23.9.
  • CONCLUSIONS: The results indicate an association between T-cell NHL and the use of cellular and cordless telephones, however based on low numbers and must be interpreted with caution.
  • Regarding B-cell NHL no association was found.
  • [MeSH-major] Cell Phones / statistics & numerical data. Lymphoma, Non-Hodgkin / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Microwaves / adverse effects. Middle Aged. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncol Res. 1999;11(11-12):539-44 [10905566.001]
  • [Cites] Radiat Res. 1997 May;147(5):631-40 [9146709.001]
  • [Cites] Leuk Lymphoma. 2001 Aug;42(4):619-29 [11697490.001]
  • [Cites] Mutat Res. 2000 Dec 20;472(1-2):51-8 [11113697.001]
  • [Cites] Radiat Res. 2002 Sep;158(3):357-64 [12175314.001]
  • [Cites] Bioelectromagnetics. 2002 Feb;23(2):113-26 [11835258.001]
  • [Cites] Mutat Res. 1992 Mar;281(3):181-6 [1371840.001]
  • [Cites] Int J Oncol. 2003 Feb;22(2):399-407 [12527940.001]
  • [Cites] J Cell Physiol. 2004 Feb;198(2):324-32 [14603534.001]
  • [Cites] Occup Environ Med. 2005 Jun;62(6):390-4 [15901886.001]
  • [Cites] Bioelectromagnetics. 1993;14(6):495-501 [8297394.001]
  • [Cites] Environ Health Perspect. 2003 Nov;111(14):1704-6 [14594618.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1353-60 [10189142.001]
  • [Cites] Bioelectromagnetics. 1992;13(6):469-96 [1482413.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 2004 Sep-Oct;7(5):351-84 [15371240.001]
  • [Cites] Bioelectromagnetics. 2003 Feb;24(2):82-90 [12524674.001]
  • [Cites] Environ Health Perspect. 2000 May;108(5):441-5 [10811571.001]
  • [Cites] Oncol Res. 1998;10(1):1-5 [9613451.001]
  • [Cites] Int J Mol Med. 2003 Jul;12(1):67-72 [12792811.001]
  • [Cites] Lancet. 1997 Jul 26;350(9073):240-4 [9242800.001]
  • (PMID = 16001209.001).
  • [ISSN] 0340-0131
  • [Journal-full-title] International archives of occupational and environmental health
  • [ISO-abbreviation] Int Arch Occup Environ Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


19. Martín-Carbonero L, Palacios R, Valencia E, Saballs P, Sirera G, Santos I, Baldobí F, Alegre M, Goyenechea A, Pedreira J, González del Castillo J, Martínez-Lacasa J, Ocampo A, Alsina M, Santos J, Podzamczer D, González-Lahoz J, Caelyx/Kaposi's Sarcoma Spanish Group: Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin. Clin Infect Dis; 2008 Aug 1;47(3):410-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Doxorubicin / analogs & derivatives. HIV Infections / complications. Lymphoma, Non-Hodgkin / complications. Neoplasm Recurrence, Local / drug therapy. Polyethylene Glycols / therapeutic use. Sarcoma, Kaposi / drug therapy
  • [MeSH-minor] Adult. CD4 Lymphocyte Count. Disease-Free Survival. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Proportional Hazards Models. Retrospective Studies

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Infect Dis. 2008 Aug 1;47(3):418-20 [18582204.001]
  • (PMID = 18582203.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase IV; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / liposomal doxorubicin; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin
  • [Investigator] González-Lahoz J; Podzamczer D; Goyenechea A; Górgolas M; Ferrer E; Valencia ME; Núñez M; Martín-Carbonero L; del Castillo JG; Téllez MJ; Galindo MJ; Baldobí F; Aldeguer JL; Berrocal A; Sirera G; Pedreira JD; Saballs P; Martínez-Lacasa J; Santos I; Sanz J; Alegre M; Torres J; Colmenero M; Santos J; Palacios R; Ocampo A
  •  go-up   go-down


20. Castelino FV, Wasfy JH, Collier D: A 36-year-old man with paresthesias and a headache. Arthritis Rheum; 2008 Sep 15;59(9):1358-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Amlodipine / therapeutic use. Biopsy. Diagnosis, Differential. Drug Therapy, Combination. Guanine / analogs & derivatives. Guanine / therapeutic use. Hepatitis B / complications. Hepatitis B / diagnosis. Hepatitis B / drug therapy. Humans. Labetalol / therapeutic use. Lymphoma, Non-Hodgkin / diagnosis. Male. Prednisone / therapeutic use. Substance Abuse, Intravenous / diagnosis. Sural Nerve / pathology. Treatment Outcome. Vasculitis / complications. Vasculitis / diagnosis. Vasculitis / drug therapy

  • MedlinePlus Health Information. consumer health - Headache.
  • Hazardous Substances Data Bank. LABETALOL .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. GUANINE .
  • Hazardous Substances Data Bank. AMLODIPINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18759310.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1J444QC288 / Amlodipine; 5968Y6H45M / entecavir; 5Z93L87A1R / Guanine; R5H8897N95 / Labetalol; VB0R961HZT / Prednisone
  •  go-up   go-down


21. Chen PM, Yen CC, Yang MH, Poh SB, Hsiao LT, Wang WS, Lin PC, Lee MY, Teng HW, Bai LY, Chu CJ, Chao SC, Yang AH, Chiou TJ, Liu JH, Chao TC: High prevalence of SV40 infection in patients with nodal non-Hodgkin's lymphoma but not acute leukemia independent of contaminated polio vaccines in Taiwan. Cancer Invest; 2006 Apr-May;24(3):223-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High prevalence of SV40 infection in patients with nodal non-Hodgkin's lymphoma but not acute leukemia independent of contaminated polio vaccines in Taiwan.
  • Recent studies have linked simian virus 40 (SV40) to non-Hodgkin's lymphoma (NHL), especially in countries in which people were exposed to contaminated polio vaccines prior to 1963.
  • Using PCR amplification of SV40 large T antigen DNA, confirmed by Southern blot hybridization and sequence analysis, 91 frozen lymph nodes from NHL patients were examined.
  • These results may reflect that human-to-human transmission of SV40 is independent of contaminated polio vaccines; and SV40 is possibly associated with the development of NHL in Taiwan (p = 0.0001).
  • [MeSH-major] Drug Contamination. Lymphoma, Non-Hodgkin / virology. Poliovirus Vaccines / adverse effects. Polyomavirus Infections / transmission. Simian virus 40
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Antigens, Polyomavirus Transforming / analysis. Blotting, Southern. Bone Marrow Cells / virology. Female. Humans. Leukemia / virology. Lymph Nodes / virology. Male. Middle Aged. Polymerase Chain Reaction. Prevalence. Taiwan. Tumor Virus Infections / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16809147.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / Poliovirus Vaccines
  •  go-up   go-down


22. Ramírez-Marrero FA, Smit E, De La Torre-Feliciano T, Pérez-Irizarry J, Miranda S, Cruz M, Figueroa-Vallés NR, Crespo CJ, Nazario CM: Risk of cancer among Hispanics with AIDS compared with the general population in Puerto Rico: 1987-2003. P R Health Sci J; 2010 Sep;29(3):256-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to determine the risk of AIDS related and non-AIDS related cancers among Hispanics with AIDS in PR.
  • RESULTS: A total of 612 cancers were identified after 3 months of AIDS diagnosis: 409 (66.7%) AIDS related and 203 (33.1%) non-AIDS related.
  • Although a decreasing trend in the risk of AIDS and non-AIDS related cancers was observed, the risk for both remained higher in the AIDS group compared to the general population in PR.
  • Non-AIDS related cancers with higher risk during the HAART availability were: oropharyngeal, anal, liver, larynx, eye and orbit, Hodgkin lymphoma, and vaginal.
  • CONCLUSION: Hispanics with AIDS in PR consistently showed a greater risk of AIDS and non-AIDS related cancers compared to the general population in PR and that has not changed over time.
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Puerto Rico / epidemiology. Risk Factors. Time Factors. Young Adult

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Hispanic American Health.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20799513.001).
  • [ISSN] 0738-0658
  • [Journal-full-title] Puerto Rico health sciences journal
  • [ISO-abbreviation] P R Health Sci J
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA096257; United States / NCI NIH HHS / CA / P20 CA096256
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Puerto Rico
  •  go-up   go-down


23. Barros MH, Zalcberg IR, Hassan R: Clinical and laboratorial prediction of bone marrow involvement in children and adolescents with Hodgkin Lymphoma. Pediatr Blood Cancer; 2008 Apr;50(4):765-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and laboratorial prediction of bone marrow involvement in children and adolescents with Hodgkin Lymphoma.
  • BACKGROUND: A risk group (RG) system to predict bone marrow involvement (BMI) based on clinical and laboratory parameters was previously shown to have prognostic value in adult patients with Hodgkin lymphoma (HL).
  • [MeSH-major] Bone Marrow / pathology. Hodgkin Disease / pathology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 17763463.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


24. Vilchez RA, Lopez-Terrada D, Middleton JR, Finch CJ, Killen DE, Zanwar P, Jorgensen JL, Butel JS: Simian virus 40 tumor antigen expression and immunophenotypic profile of AIDS-related non-Hodgkin's lymphoma. Virology; 2005 Nov 10;342(1):38-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simian virus 40 tumor antigen expression and immunophenotypic profile of AIDS-related non-Hodgkin's lymphoma.
  • Simian virus 40 (SV40) is associated with some systemic non-Hodgkin's lymphomas (NHL) among HIV-positive patients, based on assays for viral DNA sequences.
  • Fifty-five systemic NHL and 25 nonmalignant lymphoid and malignant nonlymphoid tissue control cases from two HIV community programs in Texas and New Jersey were scored for IHC positivity without knowledge of the PCR results.
  • SV40 T-ag expression was detected only in B-cell lymphoma specimens that contained SV40 DNA sequences.
  • Not all lymphoma cells in a positive specimen stained for T-ag, and the reaction was lower intensity than observed in SV40 hamster tumors.
  • A germinal center B-cell-like (GCB) profile was more frequently expressed by SV40-positive tumors than in Epstein-Barr virus (EBV)-related lymphomas (10/12, 83% vs. 6/13, 46%; P = 0.05), whereas a non-GCB phenotype was more frequent in EBV-positive than in SV40-positive lymphomas (7/13, 54% vs. 2/12, 17%; P = 0.05).
  • [MeSH-major] Antigens, Polyomavirus Transforming / genetics. Lymphoma, AIDS-Related / immunology. Lymphoma, AIDS-Related / virology. Lymphoma, Non-Hodgkin / immunology. Lymphoma, Non-Hodgkin / virology
  • [MeSH-minor] Adult. Base Sequence. Case-Control Studies. DNA, Viral / genetics. DNA, Viral / isolation & purification. Female. Gene Expression. Genes, Viral. HIV-1. Humans. Immunophenotyping. Male. Middle Aged. Molecular Sequence Data. Neoplasm Recurrence, Local / immunology. Neoplasm Recurrence, Local / virology. Simian virus 40 / genetics. Simian virus 40 / isolation & purification

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16122775.001).
  • [ISSN] 0042-6822
  • [Journal-full-title] Virology
  • [ISO-abbreviation] Virology
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI36211; United States / NCI NIH HHS / CA / CA104818
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / DNA, Viral
  •  go-up   go-down


25. Robert D, Verbiest D, Demey H, Ieven M, Jansens H, Jorens PG: A series of five adult cases of respiratory syncytial virus-related acute respiratory distress syndrome. Anaesth Intensive Care; 2008 Mar;36(2):230-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A series of five adult cases of respiratory syncytial virus-related acute respiratory distress syndrome.
  • Respiratory syncytial virus may be an underestimated cause of severe respiratory failure and acute respiratory distress syndrome in the immunocompromised adult admitted to the intensive care unit.
  • [MeSH-major] Respiratory Distress Syndrome, Adult / etiology. Respiratory Syncytial Virus Infections / complications
  • [MeSH-minor] Aged. Bronchoalveolar Lavage Fluid / microbiology. Carcinoma / complications. Colonic Neoplasms / complications. Critical Care. Fatal Outcome. Female. Granulomatosis with Polyangiitis / complications. Humans. Kidney Failure, Chronic / complications. Lymphoma, B-Cell, Marginal Zone / complications. Lymphoma, Non-Hodgkin / complications. Male. Middle Aged. Shock, Septic / etiology. Spinal Cord Neoplasms / complications


26. Vakiani E, Savage DG, Pile-Spellman E, El-Tamer M, Singh IR, Murty VS, Alobeid B, Bhagat G: T-Cell lymphoblastic lymphoma presenting as bilateral multinodular breast masses: a case report and review of the literature. Am J Hematol; 2005 Nov;80(3):216-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-Cell lymphoblastic lymphoma presenting as bilateral multinodular breast masses: a case report and review of the literature.
  • Non-Hodgkin lymphoma of T-cell lineage involving the breast is rare.
  • We report on a 41-year-old woman with T-cell lymphoblastic lymphoma who presented with multiple bilateral breast masses.
  • [MeSH-major] Breast Neoplasms / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adult. Cranial Irradiation. Diagnosis, Differential. Female. Humans. Radiotherapy, Adjuvant. Remission Induction / methods

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247747.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA149719
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Agrawal V, Doelken P, Sahn SA: Seat belt-induced chylothorax: a cause of idiopathic chylothorax? Chest; 2007 Aug;132(2):690-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chylothoraces are associated with multiple etiologies including non-Hodgkin lymphoma and surgical trauma, representing 50% and 25% of all chylothoraces, respectively.
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Pleurodesis / methods. Radiography, Thoracic. Secondary Prevention. Thoracic Surgical Procedures / methods. Tomography, X-Ray Computed. Trauma Severity Indices

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17699142.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Chiu BC, Dave BJ, Ward MH, Fought AJ, Hou L, Jain S, Gapstur S, Evens AM, Zahm SH, Blair A, Weisenburger DD: Dietary factors and risk of t(14;18)-defined subgroups of non-Hodgkin lymphoma. Cancer Causes Control; 2008 Oct;19(8):859-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary factors and risk of t(14;18)-defined subgroups of non-Hodgkin lymphoma.
  • OBJECTIVE: To evaluate the associations between diet and non-Hodgkin lymphoma (NHL) according to t(14;18) status, one of the most common chromosomal abnormalities in NHL, as t(14;18)-positive NHL represents a genetically more homogeneous group than NHL overall.
  • Information on the frequency of consumption as an adult of 30 food items was derived from the parent case-control study.
  • RESULTS: The risk of t(14;18)-positive NHL for the highest versus the lowest approximate tertile of intake was elevated for milk (OR = 2.2; 1.0-5.0) and dietary nitrite (OR = 2.8; 1.3-6.1), whereas coffee consumption was inversely associated with risk (OR = 0.4; 0.2-0.7).
  • We also found inverse associations between the intake of fish (OR = 0.5; 0.3-1.0) and carotene (OR = 0.5; 0.2-0.9) and risk of t(14;18)-negative NHL.
  • There was no association between the intake of meats, vegetables, protein, or vitamin C and risk of either t(14;18)-positive or t(14;18)-negative NHL.
  • CONCLUSION: We observed differences in associations between diet and t(14;18)-defined subgroups of NHL.
  • [MeSH-major] Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 18 / genetics. Diet. Lymphoma, Non-Hodgkin / genetics. Translocation, Genetic / genetics

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18386141.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA100555; United States / NCI NIH HHS / CA / CA132153; United States / NCI NIH HHS / CA / CA94770; United States / NCI NIH HHS / CA / K23 CA109613; United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] Netherlands
  •  go-up   go-down


29. Kitamura N, Katagiri YU, Itagaki M, Miyagawa Y, Onda K, Okita H, Mori A, Fujimoto J, Kiyokawa N: The expression of granulysin in systemic anaplastic large cell lymphoma in childhood. Leuk Res; 2009 Jul;33(7):908-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of granulysin in systemic anaplastic large cell lymphoma in childhood.
  • The expression of granulysin, a cytolytic protein produced by activated T and NK cells, has been revealed to be correlated with the prognosis of some adult cancer patients.
  • By examination on various childhood lymphoma tissues, we found that granulysin level was especially high in systemic anaplastic large cell lymphoma (ALCL) cases, whereas no close correlation with the expression of CD96, a marker for activated T and NK cells, was observed.
  • [MeSH-major] Antigens, Differentiation, T-Lymphocyte / genetics. Burkitt Lymphoma / genetics. Hodgkin Disease / genetics. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large-Cell, Anaplastic / genetics. RNA, Messenger / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD / genetics. Antigens, CD / metabolism. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Female. Flow Cytometry. Humans. Killer Cells, Natural / metabolism. Killer Cells, Natural / pathology. Male. Middle Aged. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured. Young Adult

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19243819.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Biomarkers, Tumor; 0 / CD96 antigen; 0 / GNLY protein, human; 0 / RNA, Messenger
  •  go-up   go-down


30. De Roos AJ, Davis S, Colt JS, Blair A, Airola M, Severson RK, Cozen W, Cerhan JR, Hartge P, Nuckols JR, Ward MH: Residential proximity to industrial facilities and risk of non-Hodgkin lymphoma. Environ Res; 2010 Jan;110(1):70-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Residential proximity to industrial facilities and risk of non-Hodgkin lymphoma.
  • Industrial pollution has been suspected as a cause of non-Hodgkin lymphoma (NHL), based on associations with chemical exposures in occupational studies.
  • We conducted a case-control study of NHL in four SEER regions of the United States, in which residential locations of 864 cases and 684 controls during the 10 years before recruitment were used to characterize proximity to industrial facilities reporting chemical releases to the Environmental Protection Agency's Toxics Release Inventory (TRI).
  • For each of 15 types of industry (by 2-digit SIC code), we evaluated the risk of NHL associated with having lived within 2 miles of a facility, the distance to the nearest facility (miles categories of < or =0.5, >0.5-1.0, >1.0-2.0, >2 [referent]), and the duration of residence within 2miles (years categories of 10, 1-9, 0 [referent]), using logistic regression.
  • Increased risk of NHL was observed in relation to lumber and wood products facilities (SIC 24) for the shortest distance of residential proximity (< or =0.5 mile: odds ratio [OR]=2.2, 95% confidence interval [CI]: 0.4-11.8) or the longest duration (10 years: OR=1.9, 95% CI: 0.8-4.8); the association with lumber facilities was more apparent for diffuse large B-cell lymphoma (lived within 2 miles: OR=1.7, 95% CI: 1.0-3.0) than for follicular lymphoma (OR=1.1, 95% CI: 0.5-2.2).
  • This study does not provide strong evidence that living near manufacturing industries increases NHL risk.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Apr 1;94(7):2015-23 [11932904.001]
  • [Cites] Epidemiology. 2003 Nov;14(6):687-93 [14569184.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1415-21 [15342441.001]
  • [Cites] IARC Monogr Eval Carcinog Risk Chem Hum. 1981 Feb;25:49-197 [6939657.001]
  • [Cites] Arch Environ Health. 1991 Mar-Apr;46(2):70-4 [2006896.001]
  • [Cites] Epidemiology. 2005 Jul;16(4):542-7 [15951673.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5545-52 [17545638.001]
  • [Cites] Occup Environ Med. 2009 Jan;66(1):23-31 [18805886.001]
  • [Cites] BMC Public Health. 2009;9:26 [19159450.001]
  • (PMID = 19840879.001).
  • [ISSN] 1096-0953
  • [Journal-full-title] Environmental research
  • [ISO-abbreviation] Environ. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / N01 PC067009; United States / NCI NIH HHS / CA / R03 CA115183; United States / NCI NIH HHS / CA / CA115183-02; United States / NCI NIH HHS / CA / R03 CA115183-02; None / None / / N01 PC065064; United States / NCI NIH HHS / CA / R03CA115183
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Industrial Waste
  • [Other-IDs] NLM/ NIHMS153621; NLM/ PMC2795078
  •  go-up   go-down


31. Kane EV, Painter D, Roman E, Allan J, Law G, Lightfoot T: Melanocortin 1 receptor (MC1R), pigmentary characteristics and sun exposure: findings from a case-control study of diffuse large B-cell and follicular lymphoma. Cancer Epidemiol; 2010 Apr;34(2):136-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanocortin 1 receptor (MC1R), pigmentary characteristics and sun exposure: findings from a case-control study of diffuse large B-cell and follicular lymphoma.
  • The relationship between skin cancer and non-Hodgkin lymphoma (NHL) suggests common genetic, host or environmental causes.
  • This paper reports on the relationship between MC1R, skin, hair and eye colour, time spent outdoors, and diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).
  • [MeSH-major] Lymphoma, Follicular / etiology. Lymphoma, Large B-Cell, Diffuse / etiology. Neoplasms, Radiation-Induced / etiology. Pigmentation. Receptor, Melanocortin, Type 1 / genetics. Skin Neoplasms / etiology. Sunlight / adverse effects
  • [MeSH-minor] Adolescent. Adult. Case-Control Studies. Female. Humans. Male. Middle Aged. Polymorphism, Single Nucleotide. Young Adult


32. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ: Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol; 2008 Jan 10;26(2):196-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Chi-Square Distribution. Cytarabine / administration & dosage. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Proportional Hazards Models. Research Design. Rituximab. Statistics, Nonparametric. Survival Analysis. Syndrome. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18182662.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Organoplatinum Compounds; 04079A1RDZ / Cytarabine; 04ZR38536J / oxaliplatin; 4F4X42SYQ6 / Rituximab; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


33. Pulte D, Gondos A, Brenner H: Ongoing improvement in outcomes for patients diagnosed as having Non-Hodgkin lymphoma from the 1990s to the early 21st century. Arch Intern Med; 2008 Mar 10;168(5):469-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ongoing improvement in outcomes for patients diagnosed as having Non-Hodgkin lymphoma from the 1990s to the early 21st century.
  • BACKGROUND: Non-Hodgkin lymphoma (NHL) is the most common hematologic malignant neoplasm in adults.
  • We use the novel technique of period analysis to disclose the most recent trends in survival among adults diagnosed as having NHL on the population level with minimum delay.
  • METHODS: We estimated trends in 5- and 10-year relative survival in patients 15 years or older diagnosed as having NHL in the United States between 1990 and 2004 using data from the Surveillance, Epidemiology, and End Results (SEER) program.
  • CONCLUSIONS: Our period analysis discloses a strongly improved outlook for patients diagnosed as having NHL in recent years.
  • Changes in treatment of the disease and a decrease in the number of human immunodeficiency virus-related NHL cases attributable to highly active antiretroviral therapy are probably primarily responsible for these improvements.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Outcome Assessment (Health Care)
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Continental Population Groups / statistics & numerical data. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Risk Factors. SEER Program. Survival Analysis. United States / epidemiology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18332290.001).
  • [ISSN] 0003-9926
  • [Journal-full-title] Archives of internal medicine
  • [ISO-abbreviation] Arch. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


34. Asfour IA, El-Tehewi MM, Ahmed MH, Abdel-Sattar MA, Moustafa NN, Hegab HM, Fathey OM: High-dose sodium selenite can induce apoptosis of lymphoma cells in adult patients with non-Hodgkin's lymphoma. Biol Trace Elem Res; 2009 Mar;127(3):200-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose sodium selenite can induce apoptosis of lymphoma cells in adult patients with non-Hodgkin's lymphoma.
  • The present study was undertaken to explore the effect of administration of high doses of sodium selenite on the apoptosis of lymphoma cells in patients with non-Hodgkin's lymphoma (NHL).
  • Forty patients with newly diagnosed NHL were randomly divided into two groups.
  • Flow cytometry was used for monitoring of lymphoma cells apoptosis at the time of diagnosis and after therapy in the two groups.
  • Sodium selenite administration resulted in significant increase in percentage of apoptotic lymphoma cells after therapy in group II (78.9 +/- 13.3% versus 58.9 +/- 18.9%, p < 0.05).
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Apoptosis. Lymphoma, Non-Hodgkin / drug therapy. Sodium Selenite / administration & dosage
  • [MeSH-minor] Adult. Cell Line, Tumor. Female. Humans. Male. Middle Aged

  • Hazardous Substances Data Bank. SODIUM SELENITE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18953506.001).
  • [ISSN] 1559-0720
  • [Journal-full-title] Biological trace element research
  • [ISO-abbreviation] Biol Trace Elem Res
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; HIW548RQ3W / Sodium Selenite
  •  go-up   go-down


35. Hoskin PJ, Lowry L, Horwich A, Jack A, Mead B, Hancock BW, Smith P, Qian W, Patrick P, Popova B, Pettitt A, Cunningham D, Pettengell R, Sweetenham J, Linch D, Johnson PW: Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol; 2009 Nov 10;27(32):5390-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.
  • PURPOSE: This multicenter, prospective, randomized controlled trial compared the efficacy and toxicity of two chemotherapy regimens in advanced Hodgkin's lymphoma (HL): the weekly alternating Stanford V and the standard, twice-weekly regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Bleomycin / adverse effects. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Humans. Lung Diseases / chemically induced. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / adverse effects. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19738111.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN64141244
  • [Grant] United Kingdom / Cancer Research UK / / C2422/A2858
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin
  •  go-up   go-down


36. Kuittinen T, Husso-Saastamoinen M, Sipola P, Vuolteenaho O, Ala-Kopsala M, Nousiainen T, Jantunen E, Hartikainen J: Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant; 2005 Dec;36(12):1077-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation.
  • We prospectively evaluated the very acute cardiac effects of high-dose CY in 17 adult non-Hodgkin's lymphoma (NHL) patients receiving CY 1500 mg/m2/day as a part of BEAC high-dose therapy (HDT).
  • To conclude, high-dose CY results in very acute cardiac toxicity characterised by enlargement of the heart chambers in NHL patients previously treated with anthracyclines.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Heart / drug effects. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Adult. Aged. Cardiovascular System / pathology. Carmustine / therapeutic use. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Etoposide / therapeutic use. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Natriuretic Peptides / blood. Peptides / chemistry. Prospective Studies. Time Factors. Transplantation, Autologous. Ventricular Dysfunction, Left / diagnosis. Ventricular Function, Left

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247436.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Natriuretic Peptides; 0 / Peptides; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; U68WG3173Y / Carmustine; BAEC protocol
  •  go-up   go-down


37. Salzburg J, Burkhardt B, Zimmermann M, Wachowski O, Woessmann W, Oschlies I, Klapper W, Wacker HH, Ludwig WD, Niggli F, Mann G, Gadner H, Riehm H, Schrappe M, Reiter A: Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report. J Clin Oncol; 2007 Sep 1;25(25):3915-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.
  • PURPOSE: We analyzed the prevalence, clinical pattern, and prognostic impact of CNS involvement in a large cohort of children and adolescents diagnosed with non-Hodgkin's lymphoma (NHL), with special attention to differences according to NHL subtype.
  • A total of 2,086 patients were eligible for the consecutive multicenter protocols NHL-Berlin-Frankfurt-Münster [BFM] -86, NHL-BFM-90, and NHL-BFM-95, and could be evaluated for outcome.
  • RESULTS: CNS involvement was diagnosed in 141 (5.9%) of 2,381 patients and was associated with an advanced stage of NHL.
  • The percentage of CNS-positive patients was 8.8% for Burkitt's lymphoma/Burkitt's leukemia (BL/B-ALL), 5.4% for precursor B-lymphoblastic lymphoma (pB-LBL), 3.3% for anaplastic large-cell lymphoma, 3.2% for T-cell-LBL, 2.6% for diffuse large B-cell lymphoma, and 0% for primary mediastinal large B-cell NHL (P < .001).
  • CONCLUSION: Six percent of childhood/adolescent NHL patients were CNS positive.
  • However, the prevalence, pattern, and prognostic impact of CNS involvement differed among NHL subtypes.
  • [MeSH-major] Brain Neoplasms / epidemiology. Head and Neck Neoplasms / epidemiology. Lymphoma, Non-Hodgkin / classification. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Epidural Neoplasms / epidemiology. Epidural Neoplasms / therapy. Female. Germany / epidemiology. Humans. Infant. Infant, Newborn. Male. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Prevalence. Prognosis. Treatment Failure. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17761975.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


38. Mabed M, Shamaa S: High-dose chemotherapy plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed Hodgkin disease. Biol Blood Marrow Transplant; 2006 Sep;12(9):942-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed Hodgkin disease.
  • A simplified schedule of high-dose chemotherapy consisting of cyclophosphamide (60 mg.kg(-1).d(-1) for 2 days), etoposide (15 mg.kg(-1).d(-1) for 2 days), and carboplatin (400 mg/m(2) per day for 2 days) plus autologous non-cryopreserved peripheral blood stem cells (PBSCs) was used for treatment of patients with relapsed (n = 25) and refractory (n = 3) Hodgkin disease.
  • High-dose chemotherapy with short-duration chemotherapy and non-cryopreserved bone marrow is an effective and safe treatment modality for patients with relapsed or resistant Hodgkin lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hodgkin Disease / prevention & control. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Carboplatin / administration & dosage. Cryopreservation. Cyclophosphamide / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Recurrence. Retrospective Studies. Time Factors. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16920560.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


39. Clifford GM, Rickenbach M, Lise M, Dal Maso L, Battegay M, Bohlius J, Boffi El Amari E, Karrer U, Jundt G, Bordoni A, Ess S, Franceschi S, Swiss HIV Cohort Study: Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood; 2009 Jun 4;113(23):5737-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma in the Swiss HIV Cohort Study.
  • Hodgkin lymphoma (HL) risk is elevated among persons infected with HIV (PHIV) and has been suggested to have increased in the era of combined antiretroviral therapy (cART).
  • [MeSH-major] HIV Infections / complications. HIV Infections / epidemiology. Hodgkin Disease / complications. Hodgkin Disease / epidemiology
  • [MeSH-minor] Adult. Biomarkers. Cohort Studies. Female. Humans. Male. Middle Aged. Switzerland / epidemiology


40. Israel R, Dorer R, Aboulafia DM: Case report of human immunodeficiency virus infection, Hodgkin lymphoma, and pregnancy. Am J Med Sci; 2010 Feb;339(2):185-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report of human immunodeficiency virus infection, Hodgkin lymphoma, and pregnancy.
  • As the incidence of human immunodeficiency virus (HIV) infection in women of child bearing age continues to increase in the era of highly active antiretroviral therapy and Hodgkin lymphoma (HL) is the most common non-acquired immunodeficiency syndrome defining malignancy, we anticipate that the number of cases of HIV-associated HL in pregnant women will increase in the near future.
  • [MeSH-major] HIV Infections / complications. Hodgkin Disease / complications. Pregnancy
  • [MeSH-minor] Adult. Anti-HIV Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Female. Humans. Viral Load


41. Colović N, Terzić T, Andelić B, Sretenović M, Mihaljević B, Lipkovski JM, Colović M: Nephrotic syndrome and acute renal failure in non-Hodgkin lymphoplasmacytic lymphoma. Med Oncol; 2008;25(4):458-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nephrotic syndrome and acute renal failure in non-Hodgkin lymphoplasmacytic lymphoma.
  • Two patients with lymphoplasmacytic lymphoma, and monoclonal proteins of IgM in one, and IgG and lambda light chains in the second patient, nephrotic syndrome and acute renal failure are reported.
  • A 58-year-old man previously treated for pre-B acute lymphoblastic leukemia, developed 3 years later nephrotic syndrome as a complication of lymphoplasmacytic lymphoma and high-paraprotein IgM kappa type.
  • The second patient is a 42-year-old female diagnosed with lymphoplasmacytic lymphoma and paraprotein IgG lambda type.
  • [MeSH-major] Acute Kidney Injury / complications. Lymphoma, Non-Hodgkin / complications. Nephrotic Syndrome / complications. Waldenstrom Macroglobulinemia / complications
  • [MeSH-minor] Adult. Fatal Outcome. Female. Fluorescent Antibody Technique. Humans. Immunoglobulin G. Immunoglobulin M. Immunohistochemistry. Male. Middle Aged

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med. 1975 Apr;58(4):567-75 [804814.001]
  • [Cites] Am J Kidney Dis. 2001 Nov;38(5):1135-40 [11684573.001]
  • [Cites] Clin Exp Immunol. 1980 Aug;41(2):196-204 [6777101.001]
  • [Cites] N Engl J Med. 1970 Jul 16;283(3):123-9 [4987279.001]
  • [Cites] Annu Rev Med. 1989;40:53-60 [2499246.001]
  • [Cites] Kidney Int. 2004 Jan;65(1):85-96 [14675039.001]
  • (PMID = 18214715.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Immunoglobulin M
  •  go-up   go-down


42. Ribeiro-Silva A, Mendes CF, Costa IS, de Moura HB, Tiezzi DG, Andrade JM: Metastases to the breast from extramammary malignancies: a clinicopathologic study of 12 cases. Pol J Pathol; 2006;57(3):161-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological diagnoses of the primary tumor were as follows: non-Hodgkin diffuse large B-cell lymphoma (3 patients), acute mycloid leukemia (3 patients), serous papillary adenocarcinoma, well-differentiated adenocarcinoma, squamous cell carcinoma, undifferentiated neoplasm, mesothelioma, and melanoma.
  • [MeSH-minor] Adolescent. Adult. Aged. Breast Neoplasms, Male / radiography. Breast Neoplasms, Male / secondary. Child. Female. Humans. Male. Mammography. Middle Aged. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17219743.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


43. Thapar N, Shah N, Ramsay AD, Lindley KJ, Milla PJ: Long-term outcome of intractable ulcerating enterocolitis of infancy. J Pediatr Gastroenterol Nutr; 2005 May;40(5):582-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These comprised a monomorphous B-lymphoycte lympho-proliferative disorder, a large pleomorphic follicular lymphoma, and a high grade pleomorphic B cell non-Hodgkin's lymphoma.
  • [MeSH-minor] Adolescent. Adult. Azathioprine / therapeutic use. Child. Child, Preschool. Chronic Disease. Cyclosporine / therapeutic use. Epstein-Barr Virus Infections / epidemiology. Female. Follow-Up Studies. Humans. Immunoglobulins / therapeutic use. Infant. Infant, Newborn. Lymphoma, Non-Hodgkin / epidemiology. Lymphoproliferative Disorders / epidemiology. Male. Steroids / therapeutic use. Thalidomide / therapeutic use. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15861020.001).
  • [ISSN] 0277-2116
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulins; 0 / Immunosuppressive Agents; 0 / Steroids; 4Z8R6ORS6L / Thalidomide; 83HN0GTJ6D / Cyclosporine; MRK240IY2L / Azathioprine
  •  go-up   go-down


44. Attygalle AD, Kyriakou C, Dupuis J, Grogg KL, Diss TC, Wotherspoon AC, Chuang SS, Cabeçadas J, Isaacson PG, Du MQ, Gaulard P, Dogan A: Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression. Am J Surg Pathol; 2007 Jul;31(7):1077-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression.
  • Angioimmunoblastic T-cell lymphoma (AITL) is an uncommon, but aggressive nodal peripheral T-cell lymphoma.
  • Seven cases (23%) developed EBV-associated B-cell lymphomas [5 diffuse large B-cell lymphoma (DLBCL) and 2 classic Hodgkin lymphoma].
  • When "morphologic high-grade transformation" occurs, it is usually due to a secondary (often EBV-associated) B-cell lymphoma, rather than a T-cell neoplasm.
  • [MeSH-major] Lymph Nodes / pathology. Lymphoma, T-Cell, Peripheral / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Biopsy. Clone Cells / metabolism. Clone Cells / pathology. Disease Progression. Disease-Free Survival. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / metabolism. Epstein-Barr Virus Infections / pathology. Female. Gene Rearrangement, T-Lymphocyte. Herpesvirus 4, Human / isolation & purification. Humans. In Situ Hybridization. Male. Middle Aged. Neoplasm Staging. RNA, Viral / analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17592275.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA97274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Viral
  •  go-up   go-down


45. Kurtz DM, Tschetter LK, Allred JB, Geyer SM, Kurtin PJ, Putnam WD, Rowland KM Jr, Wiesenfeld M, Soori GS, Tenglin RC, Bernath AM, Witzig TE: Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51. Leuk Lymphoma; 2007 Jul;48(7):1290-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51.
  • Interleukin-4 (IL-4), a pleiotropic cytokine, has in vitro activity against non-Hodgkin lymphoma (NHL).
  • This phase II study was conducted to learn the efficacy and toxicity of IL-4 in patients with NHL.
  • Patients with relapsed or refractory indolent or aggressive NHL were eligible to receive 2.5 or 5.0 mcg/kg of subcutaneous IL-4 for 28 days of a 42-day cycle.
  • Agents that target the IL-4 receptor can potentially benefit patients with NHL; however, alternative schedules using IL-4 in shorter duration and in combination with other agents would be required to overcome toxicities observed in this study.
  • [MeSH-major] Interleukin-4 / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Recurrence. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 Jul;48(7):1259-60 [17613750.001]
  • [CommentIn] Leuk Lymphoma. 2007 Jul;48(7):1261-3 [17613751.001]
  • (PMID = 17613756.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-15083; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-35113; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / CA-35269; United States / NCI NIH HHS / CA / CA-35448; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-52352; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / CA-63849
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 207137-56-2 / Interleukin-4
  •  go-up   go-down


46. Toure G, Roucayrol AM, Meningaud JP, Bertrand JC: Plasmablastic lymphoma: a case report. Quintessence Int; 2007 Feb;38(2):161-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma: a case report.
  • Plasmablastic lymphoma is a rare subcategory of non-Hodgkin lymphoma frequently associated with human immunodeficiency virus.
  • It is a large B-cell lymphoma that has a predilection for the oral cavity.
  • Clinically, plasmablastic lymphoma may mislead to a diagnosis of Kaposi's sarcoma.
  • When infected, plasmablastic lymphoma may mimic an odontogenic cellulitis.
  • [MeSH-major] HIV-1. Lymphoma, AIDS-Related / pathology. Maxillary Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Male


47. Mols F, Vingerhoets AJ, Coebergh JW, Vreugdenhil G, Aaronson NK, Lybeert ML, van de Poll-Franse LV: Better quality of life among 10-15 year survivors of Hodgkin's lymphoma compared to 5-9 year survivors: a population-based study. Eur J Cancer; 2006 Nov;42(16):2794-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Better quality of life among 10-15 year survivors of Hodgkin's lymphoma compared to 5-9 year survivors: a population-based study.
  • This study describes the quality of life (QoL) of long-term Hodgkin's lymphoma survivors and compares it to an age-matched normative sample.
  • The population-based Eindhoven Cancer Registry was used to select all patients diagnosed with Hodgkin's lymphoma from 1989 to 1998.
  • QoL among Hodgkin's lymphoma survivors is lower compared to an age-matched normative sample.
  • [MeSH-major] Hodgkin Disease / mortality. Quality of Life. Survivors / statistics & numerical data
  • [MeSH-minor] Adult. Age of Onset. Aged. Cross-Sectional Studies. Female. Humans. Male. Middle Aged. Netherlands / epidemiology. Surveys and Questionnaires. Time Factors

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16996260.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


48. Genebat M, Ruiz-Mateos E, Pulido I, González-Serna A, García-Pergañeda A, Méndez G, Romero-Sánchez MC, Ferrando-Martínez S, Leal M: Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice. Curr HIV Res; 2010 Sep;8(6):482-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One patient developed a non-Hodgkin lymphoma after 36 weeks follow up, despite undetectable viral load and significant CD4+ increase was achieved (the only AIDS-defining event observed).
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Female. HIV Protease Inhibitors / therapeutic use. HIV-1 / drug effects. Humans. Male. Middle Aged. Pyrrolidinones / therapeutic use. Raltegravir Potassium. Retrospective Studies. Spain. Time. Viral Load


49. Geurts DE, van der Velden WJ, Hebeda KM, Raemaekers JM: Richter's syndrome developing in a patient with adult onset Still's disease. Ann Hematol; 2009 Jan;88(1):81-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Richter's syndrome developing in a patient with adult onset Still's disease.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / etiology. Lymphoma, Non-Hodgkin / etiology. Still's Disease, Adult-Onset / complications
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Middle Aged. Syndrome

  • Genetic Alliance. consumer health - Still's disease adult onset.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18607590.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  •  go-up   go-down


50. Cronin DP, Harlan LC, Clegg LX, Stevens JL, Yuan G, Davis TA: Patterns of care in a population-based random sample of patients diagnosed with non-Hodgkin's lymphoma. Hematol Oncol; 2005 Jun;23(2):73-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of care in a population-based random sample of patients diagnosed with non-Hodgkin's lymphoma.
  • New therapies have enhanced treatment of non-Hodgkin's lymphoma (NHL), but extent of treatment use in community practice is unknown.
  • We conducted a population-based study of NHL patients diagnosed in 1999 with histologically confirmed NHL (n = 947) residing in areas covered by the Surveillance, Epidemiology, and End Results program.
  • Most patients presented with B-cell lymphoma (n = 828).
  • Hispanic and African-Americans, patients age 75 +, males, unmarried patients, or patients with B-symptoms had higher risk of death from NHL and all-cause (p < 0.01).
  • This is the first population-based study examining therapy received for many histological subtypes of NHL.
  • [MeSH-major] Community Health Services. Lymphoma, Non-Hodgkin / therapy. Practice Patterns, Physicians'
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cause of Death. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Registries. Risk Factors. Rituximab

  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16170828.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-35133; United States / NCI NIH HHS / PC / N01-PC-35135; United States / NCI NIH HHS / PC / N01-PC-35136; United States / NCI NIH HHS / PC / N01-PC-35137; United States / NCI NIH HHS / PC / N01-PC-35138; United States / NCI NIH HHS / PC / N01-PC-35139; United States / NCI NIH HHS / PC / N01-PC-35141; United States / NCI NIH HHS / PC / N01-PC-35142; United States / NCI NIH HHS / PC / N01-PC-35143; United States / NCI NIH HHS / PC / N01-PC-35145
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


51. Weycker D, Malin J, Kim J, Barron R, Edelsberg J, Kartashov A, Oster G: Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. Clin Ther; 2009 May;31(5):1069-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Breast cancer was the most common tumor type (52% and 51%), followed by non-Hodgkin's lymphoma (21% and 18%) and lung cancer (11% and 15%).
  • [MeSH-major] Antineoplastic Agents / adverse effects. Breast Neoplasms / drug therapy. Granulocyte Colony-Stimulating Factor / therapeutic use. Hospitalization / statistics & numerical data. Lung Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Neutropenia / chemically induced
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Filgrastim. Humans. Male. Middle Aged. Odds Ratio. Recombinant Proteins. Retrospective Studies. Risk. Treatment Outcome. United States. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. Filgrastim .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19539108.001).
  • [ISSN] 0149-2918
  • [Journal-full-title] Clinical therapeutics
  • [ISO-abbreviation] Clin Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A58010674 / pegfilgrastim; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


52. Halpern MT, Ward EM, Pavluck AL, Schrag NM, Bian J, Chen AY: Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol; 2008 Mar;9(3):222-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, patients with cancer from ethnic minorities are more likely to be uninsured or Medicaid-insured than non-Hispanic white people.
  • Odds ratios and 95% CIs for the effect of insurance status (Medicaid, Medicare (65-99 years), Medicare (18-64 years), private, or uninsured) and ethnicity (white, Hispanic, black, or other) on disease stage at diagnosis for 12 cancer sites (breast [female], colorectal, kidney, lung, melanoma, non-Hodgkin lymphoma, ovary, pancreas, prostate, urinary bladder, uterus, and thyroid) were estimated, while controlling for patient characteristics.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Databases, Factual. Ethnic Groups. Female. Humans. Male. Middle Aged. Registries. Retrospective Studies. Severity of Illness Index. United States

  • MedlinePlus Health Information. consumer health - Medicaid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2008 Mar;9(3):189-91 [18308240.001]
  • (PMID = 18282806.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


53. von Falck C, Rodt T, Joerdens S, Waldeck S, Kiesel H, Knapp WH, Galanski M: F-18 2-fluoro-2-deoxy-glucose positron emission tomography/computed tomography for the detection of radicular and peripheral neurolymphomatosis: correlation with magnetic resonance imaging and ultrasound. Clin Nucl Med; 2009 Aug;34(8):493-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurolymphomatosis is an uncommon extranodal manifestation of non-Hodgkin lymphoma.
  • Recently, a few reports have been published that discuss a possible advantage of F-18 2-fluoro-2-deoxy-glucose positron emission tomography/computed tomography (F-18 FDG PET/CT) in these patients.We report the case of a 41-year-old man who presented with progressive tetraparesis and dysaesthesia, in which F-18 FDG PET/CT aided to the diagnosis of neurolymphomatosis due to a large B-cell lymphoma.
  • [MeSH-major] Fluorodeoxyglucose F18. Lymphoma, B-Cell / diagnosis
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male. Neoplasm Staging. Positron-Emission Tomography. Recurrence. Tomography, X-Ray Computed

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617723.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


54. Freedman RJ, Malkovska V, LeRoith D, Collins MT: Hodgkin lymphoma in temporal association with growth hormone replacement. Endocr J; 2005 Oct;52(5):571-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma in temporal association with growth hormone replacement.
  • We report a case of Hodgkin lymphoma that developed in temporal association with the initiation of GH replacement in a 57-year-old woman with panhypopituitarism secondary to a non-secretory pituitary macroadenoma.
  • Approximately 2 years after GH initiation, the diagnosis of Hodgkin lymphoma was made.
  • Although the exact contribution of GH to the development of Hodgkin disease in our patient is unclear and a causal effect cannot be concluded, the temporal association is suggestive, and warrants reporting as part of ongoing surveillance for potential complications of GH replacement.
  • [MeSH-major] Hodgkin Disease / chemically induced. Human Growth Hormone / therapeutic use
  • [MeSH-minor] Adenoma / therapy. Adult. Female. Humans. Middle Aged. Pituitary Neoplasms / therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16284435.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


55. Yao B, Li YX, Fang H, Jin J, Liu XF, Yu ZH: [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases]. Ai Zheng; 2006 Apr;25(4):465-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
  • BACKGROUND & OBJECTIVE: The prognosis of primary non-Hodgkin's lymphoma (NHL) of the nasal cavity was poor, and the distant metastasis and local relapse rates are high.
  • METHODS: Clinical data of 129 patients with pathologically confirmed nasal NHL, treated from Jan.
  • Of the 129 patients, 116 were diagnosed as nasal NK/T-cell lymphoma.
  • CONCLUSIONS: CR rate after treatment is an important prognostic factor of nasal NHL.
  • Distant metastasis is the main failure pattern of nasal NHL.
  • [MeSH-major] Lymphoma, Extranodal NK-T-Cell / therapy. Lymphoma, Non-Hodgkin / therapy. Nasal Cavity. Nose Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / radiotherapy. Lymphoma, B-Cell / therapy. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prednisone / therapeutic use. Remission Induction. Survival Rate. Vincristine / therapeutic use. Young Adult

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613682.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


56. Cortelezzi A, Fracchiolla NS, Mazzeo LM, Silvestris I, Pomati M, Somalvico F, Bertolini F, Mancuso P, Pruneri GC, Gianelli U, Pasquini MC, Cortiana M, Deliliers GL: Endothelial precursors and mature endothelial cells are increased in the peripheral blood of myelodysplastic syndromes. Leuk Lymphoma; 2005 Sep;46(9):1345-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, increased circulating endothelial cells (CECs) have been associated with breast cancer and non-Hodgkin lymphoma (NHL).
  • [MeSH-minor] Adult. Aged. Biomarkers. Bone Marrow / blood supply. Cell Count. Female. Flow Cytometry. Humans. Male. Middle Aged. Stem Cells / physiology


57. Perseghin P, Terruzzi E, Dassi M, Baldini V, Parma M, Coluccia P, Accorsi P, Confalonieri G, Tavecchia L, Verga L, Ravagnani F, Iacone A, Pogliani EM, Pioltelli P: Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions. Transfus Apher Sci; 2009 Aug;41(1):33-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Antigens, CD34 / blood. Follow-Up Studies. Hematopoiesis. Hematopoietic Stem Cell Mobilization / methods. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / surgery. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery. Leukemia, Myeloid, Acute / surgery. Lymphoma, Non-Hodgkin / surgery. Multiple Myeloma / surgery. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19540167.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


58. Delgado WA, Romero de Leon E: 14th International Congress IAOP/AAOMP Clinical Pathology Conference Case 6. Head Neck Pathol; 2008 Dec;2(4):298-301
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Bacterial Infections / diagnosis. Cryptococcus neoformans / isolation & purification. Diagnosis, Differential. Humans. Immunocompromised Host. Lymphoma, Non-Hodgkin / diagnosis. Male. Mycoses / diagnosis. Sarcoma, Kaposi / diagnosis

  • MedlinePlus Health Information. consumer health - Gum Disease.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br Dent J. 2001 Apr 28;190(8):420-2 [11352389.001]
  • [Cites] Crit Rev Oral Biol Med. 2003;14(5):377-83 [14530306.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1987 Oct;64(4):449-53 [3477766.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1987 Oct;64(4):454-9 [3477767.001]
  • [Cites] J Oral Maxillofac Surg. 1989 Aug;47(8):849-52 [2746395.001]
  • [Cites] J Oral Maxillofac Surg. 1992 Jul;50(7):759-60 [1608008.001]
  • [Cites] J Oral Pathol Med. 1997 Jul;26(6):294-6 [9234191.001]
  • [Cites] J Infect Chemother. 2005 Jun;11(3):115-22 [15990974.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Oct;63(10):1543-9 [16182927.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Feb;105(2):194-201 [17604660.001]
  • (PMID = 20614298.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Congresses
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2807577
  • [Keywords] NOTNLM ; Acquired immunodeficiency syndrome / Cryptococcosis / Diagnosis / Gingiva / HIV
  •  go-up   go-down


59. Sanna G, Lorizzo K, Rotmensz N, Bagnardi V, Cinieri S, Colleoni M, Nolè F, Goldhirsch A: Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors. Ann Oncol; 2007 Feb;18(2):288-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors.
  • BACKGROUND: Better therapeutic approaches for patients with Hodgkin's disease (HD) and non-Hodgkin's lymphomas (NHL) resulted in high cure rates, at cost of serious late side effects.
  • MATERIALS AND METHODS: Fifty-three women treated for primary BC with previous history of malignant lymphoma were identified in our institution, 35 with HD (66%), 18 (34%) with NHL.
  • A comparison group was randomly selected from our database matching for each patient with previous lymphoma, two patients with primary BC (rate 1 : 2) for age, stage (pathological tumour size [pT] status and nodal status), year of diagnosis, and estrogen and progesterone status (positive versus negative).
  • Considering these variables, no significant differences were observed between the two groups with the exception of Ki-67, which was found higher in those with previous HD or NHL (65% versus 49%, respectively, P = 0.0526, borderline significant).
  • However, regarding patients with node-positive disease (14 versus 35 patients), five patients in the lymphoma group (36%), compared with 24 (69%) in the matched group received anthracycline-based therapy (P = 0.0345).
  • CONCLUSIONS: Previous history of malignant lymphoma is a negative prognostic factor for women diagnosed subsequently with BC.


60. Niens M, Jarrett RF, Hepkema B, Nolte IM, Diepstra A, Platteel M, Kouprie N, Delury CP, Gallagher A, Visser L, Poppema S, te Meerman GJ, van den Berg A: HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. Blood; 2007 Nov 1;110(9):3310-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma.
  • Previous studies showed that the HLA class I region is associated with Epstein-Barr virus (EBV)-positive Hodgkin lymphoma (HL) and that HLA-A is the most likely candidate gene in this region.
  • [MeSH-major] Epstein-Barr Virus Infections / genetics. HLA-A Antigens / genetics. Hodgkin Disease / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Genetic Predisposition to Disease. HLA-A1 Antigen. HLA-A2 Antigen. Haplotypes. Humans. Male. Middle Aged. Polymorphism, Single Nucleotide. Risk Factors

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17630352.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA-A Antigens; 0 / HLA-A*02 antigen; 0 / HLA-A1 Antigen; 0 / HLA-A2 Antigen
  •  go-up   go-down


61. Krishnan A, Nademanee A, Fung HC, Raubitschek AA, Molina A, Yamauchi D, Rodriguez R, Spielberger RT, Falk P, Palmer JM, Forman SJ: Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol; 2008 Jan 1;26(1):90-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
  • PURPOSE: This phase II trial evaluated the safety and efficacy of combining yttrium-90 (90Y) ibritumomab tiuxetan with high-dose carmustine, cytarabine, etoposide, and melphalan (BEAM) and autologous stem-cell transplantation in patients with non-Hodgkin's lymphoma who were considered ineligible for total-body irradiation because of older age or prior radiotherapy.
  • PATIENTS AND METHODS: Between May 2002 and January 2006, 14 days before autologous stem-cell transplantation, 41 patients with non-Hodgkin's lymphoma received standard-dose 90Y ibritumomab tiuxetan (14.8 MBq/kg [0.4 mCi/kg]) followed by high-dose BEAM.
  • Disease histologies were diffuse large B-cell (n = 20), mantle cell (n = 13), follicular (n = 4), and transformed lymphoma (n = 4).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / therapy. Radioimmunotherapy. Stem Cell Transplantation. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Adult. Aged. Carmustine / therapeutic use. Combined Modality Therapy. Cytarabine / therapeutic use. Disease-Free Survival. Female. Humans. Lymphoma, Follicular / pathology. Lymphoma, Follicular / therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, Mantle-Cell / pathology. Lymphoma, Mantle-Cell / therapy. Male. Melphalan / therapeutic use. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Podophyllotoxin / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. PODOFILOX .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18025438.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR0043; United States / NCI NIH HHS / CA / P01 CA030206; United States / NCI NIH HHS / CA / P30CA3357
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan; 04079A1RDZ / Cytarabine; L36H50F353 / Podophyllotoxin; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; BEAM protocol
  •  go-up   go-down


62. Zell JA, Yoon EJ, Ignatius Ou SH, Hoefs JC, Chang JC: Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab. Anticancer Drugs; 2005 Jan;16(1):83-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A patient with stage IV non-Hodgkin's lymphoma and chronic hepatitis who was treated with chemotherapy and rituximab developed fatal reactivation of hepatitis B.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hepatitis B / chemically induced. Lymphoma, Non-Hodgkin / drug therapy. Virus Activation / drug effects
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Fatal Outcome. Hepatitis B virus / drug effects. Hepatitis B virus / physiology. Humans. Male. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / adverse effects. Recurrence. Rituximab. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15613909.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


63. Salour H, Hatami MM, Parvin M, Ferdowsi AA, Abrishami M, Bagheri A, Aletaha M, Yazdani S: Clinicopathological study of lacrimal sac specimens obtained during DCR. Orbit; 2010 Oct;29(5):250-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To determine the histopathologic characteristics of lacrimal sac specimens in adult patients undergoing external dacryocystorhinostomy (DCR) for acquired nasolacrimal duct obstruction.
  • Histopathologic findings included: chronic inflammation in 450 patients (95.5%), fibrosis in 18 patients (3.8%), lymphoma in two patients (0.4%) and reactive lymphoid hyperplasia in one patient (0.2%).
  • Lacrimal sac appearance during surgery was grossly abnormal in two cases: one case of lymphoma and one instance of reactive lymphoid hyperplasia.
  • Only two cases of lymphoma (0.4%) were encountered in the series, one of which had a suspicious lacrimal sac appearance during surgery while the other case (0.2% of all specimens) was unsuspected.
  • [MeSH-major] Dacryocystitis / diagnosis. Dacryocystorhinostomy. Lacrimal Duct Obstruction / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Nasolacrimal Duct / pathology. Pseudolymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Child. Child, Preschool. Female. Fibrosis / diagnosis. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20812824.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


64. Seshadri T, Pintilie M, Keating A, Crump M, Kuruvilla J: The relationship between absolute lymphocyte count with PFS in patients with Hodgkin's lymphoma undergoing autologous hematopoietic cell transplant. Bone Marrow Transplant; 2008 Jul;42(1):29-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship between absolute lymphocyte count with PFS in patients with Hodgkin's lymphoma undergoing autologous hematopoietic cell transplant.
  • Previous reports in Hodgkin's lymphoma (HL) patients undergoing autologous hematopoietic cell transplantation (AHCT) have demonstrated a significant association between the absolute lymphocyte count at day 15 (ALC-15) with survival.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Hodgkin Disease / therapy. Lymphocyte Count
  • [MeSH-minor] Adolescent. Adult. Aged. Blood Component Removal. Disease-Free Survival. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Transplantation Conditioning. Transplantation, Autologous

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18332908.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


65. Nogovà L, Diehl V, Engert A, German Hodgkin Study Group: Nodular lymphocyte-predominant Hodgkin's lymphoma. Curr Hematol Malig Rep; 2006 Mar;1(1):60-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular lymphocyte-predominant Hodgkin's lymphoma.
  • Lymphocyte-predominant Hodgkin's lymphoma (LPHL) differs in histologic and clinical presentation from classical Hodgkin's lymphoma (cHL).
  • Treatment of LPHL patients using standard Hodgkin's lymphoma protocols leads to complete remission in more than 95% of patients.
  • IF-RT seems to be emerging as a treatment of choice for patients with stage IA LPHL; most larger study groups, such as the German Hodgkin Study Group and the European Organisation for Research and Treatment of Cancer, have adopted IF-RT as the treatment of choice for these patients.
  • [MeSH-major] Hodgkin Disease / pathology
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Clinical Trials as Topic. Combined Modality Therapy. Disease-Free Survival. Histiocytes / pathology. Humans. Lymphocytes / pathology. Neoplasm Staging. Patient Selection. Prognosis. Radiotherapy Dosage. Remission Induction. Rituximab. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Mar 15;94(6):1731-8 [11920535.001]
  • [Cites] Cancer. 2005 Sep 15;104(6):1221-9 [16094666.001]
  • [Cites] Histopathology. 1990 Feb;16(2):157-65 [2323737.001]
  • [Cites] Blood. 2004 Jan 1;103(1):188-93 [12881301.001]
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:77-82 [2049323.001]
  • [Cites] Ann Oncol. 1995 Jul;6(6):559-65 [8573534.001]
  • [Cites] Cancer. 1987 Jan 1;59(1):99-106 [3791150.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9337-42 [9256483.001]
  • [Cites] Cancer J. 2002 Sep-Oct;8(5):377-83 [12416895.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Sep;25(9):684-7 [12972802.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4285-9 [12586628.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):106-10 [16007877.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1683-7 [16093276.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5739-45 [16009944.001]
  • [Cites] Eur J Cancer. 2002 Mar;38 Suppl 4:S107-13 [11858975.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2675-81 [15231567.001]
  • [Cites] Leuk Lymphoma. 2003 Nov;44(11):1903-10 [14738141.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2005 Feb;17(1):47-53 [15714929.001]
  • [Cites] Blood. 2003 Jan 15;101(2):420-4 [12509381.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2948-52 [12885814.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):776-83 [10071266.001]
  • [Cites] Lancet Oncol. 2004 Jan;5(1):11-8 [14700604.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1889-99 [10961891.001]
  • (PMID = 20425333.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 25
  •  go-up   go-down


66. Talamini R, Polesel J, Montella M, Dal Maso L, Crovatto M, Crispo A, Spina M, Canzonieri V, La Vecchia C, Franceschi S: Food groups and risk of non-Hodgkin lymphoma: a multicenter, case-control study in Italy. Int J Cancer; 2006 Jun 1;118(11):2871-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Food groups and risk of non-Hodgkin lymphoma: a multicenter, case-control study in Italy.
  • Incidence of non-Hodgkin lymphoma (NHL) has been rising worldwide, but the reasons are undefined.
  • Dietary habits may play a role in the etiology of NHL by influencing the metabolic pathways of several cells of the immune system.
  • This case-control study investigated the relation between food consumption and NHL risk.
  • Between 1999 and 2002, we conducted a hospital-based case-control study on NHL in 2 areas of Italy.
  • Cases were 190 patients (median age 58 years) with incident NHL admitted to specialized and general hospitals.
  • Controls were 484 patients (median age 63 years) with acute non-neoplastic conditions admitted to the same hospitals network of cases.
  • Consumption of highest versus lowest quartile of pasta/rice (OR = 1.87, 95% CI: 1.04-3.36) and cheese (OR = 1.66, 95% CI: 0.98-2.83) were associated with a significantly increased NHL risk.
  • In conclusion, our results suggested that diet could affect NHL risk.
  • [MeSH-major] Diet. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / etiology
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Food. Humans. Italy / epidemiology. Male. Middle Aged. Odds Ratio. Risk Factors

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16385566.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


67. Diamond C, Taylor TH, Anton-Culver H: Quality of life, characteristics and survival of patients with HIV and lymphoma. Qual Life Res; 2010 Mar;19(2):149-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life, characteristics and survival of patients with HIV and lymphoma.
  • PURPOSE: We sought to compare the quality of life (QOL), characteristics, and survival of patients with non-Hodgkin lymphoma (NHL) with and without human immunodeficiency virus (HIV) infection.
  • METHODS: Using the population-based cancer registry for Orange and San Diego Counties, We recruited 50 patients with HIV and systemic NHL (cases) and 50 age, sex and race-matched NHL patients without HIV (controls) diagnosed with NHL during 2002-2006.
  • CONCLUSION: HIV-infected NHL patients had worse QOL and survival than uninfected patients, due to a combination of co-morbidity, aggressive histology and lack of social support.
  • However, their emotional well-being was comparable to that of uninfected NHL patients and better than historical norms for the HIV-infected.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Living with HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © The Author(s) 2010. This article is published with open access at Springerlink.com
  • [Cites] Am J Hematol. 2001 Mar;66(3):178-88 [11279624.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Jul 1;15(3):211-22 [9257656.001]
  • [Cites] Qual Life Res. 1997 Aug;6(6):572-84 [9330556.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Med Care. 1998 Sep;36(9):1407-18 [9749663.001]
  • [Cites] Eval Health Prof. 2005 Jun;28(2):192-211 [15851773.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):128-35 [16329140.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4123-8 [16896005.001]
  • [Cites] Cancer Causes Control. 2007 Mar;18(2):135-42 [17235495.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):960-6 [19139438.001]
  • [Cites] Med Care. 2003 May;41(5):582-92 [12719681.001]
  • [Cites] Appl Health Econ Health Policy. 2003;2(2):85-90 [14619279.001]
  • [Cites] Cochrane Database Syst Rev. 2009;(3):CD005419 [19588373.001]
  • [Cites] Qual Life Res. 1996 Aug;5(4):450-63 [8840825.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):570-9 [8445433.001]
  • (PMID = 20058087.001).
  • [ISSN] 1573-2649
  • [Journal-full-title] Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
  • [ISO-abbreviation] Qual Life Res
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K07 CA096480; United States / NCI NIH HHS / CA / P30 CA062203; United States / NCI NIH HHS / CA / K07 CA96480
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


68. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H: Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer; 2006 Apr 1;106(7):1569-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
  • BACKGROUND: Adult Burkitt-type lymphoma (BL) and acute lymphoblastic leukemia (B-ALL) are rare entities composing 1% to 5% of non-Hodgkin lymphomas NHL) or ALL.
  • Prognosis of BL and B-ALL has been poor with conventional NHL or ALL regimens, but has improved with dose-intensive regimens.
  • CONCLUSIONS: The addition of rituximab to hyper-CVAD may improve outcome in adult BL or B-ALL, particularly in elderly patients.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


69. Omoti CE: Socio-demographic factors of adult malignant lymphomas in Benin City, Nigeria. Niger Postgrad Med J; 2006 Sep;13(3):256-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Socio-demographic factors of adult malignant lymphomas in Benin City, Nigeria.
  • AIM: The aim of this study is to determine the incidence and sociodemographic factors associated with adult malignant lymphoma in Benin City, Niger Delta region of Nigeria.
  • METHOD: A retrospective study of 205 patients with a diagnosis of lymphoma seen over a 13-year period (1990-2003) at the University of Benin Teaching Hospital, Nigeria.
  • Non-Hodgkin's lymphoma (NHL) was more frequent (83%) while Hodgkin's lymphoma had incidence of 17%.
  • Marital status (P = 0.0002), geographical abode (p = 0.0046), educational (P = 0.0045) and occupational status (p = 0.0001) were significantly associated with the malignant lymphoma at presentation.
  • All the lymphoma subtypes were most common in patients who resided in Delta state, a major oil producer.
  • The majority of the lymphoma patients (46.3%) had tertiary form of education.
  • The highest and lowest social classes were most likely to have lymphoma, which may have been related to age and industrial exposure.
  • Living in Delta State where the petrochemical industries and gas flare sites are located may be a risk factor for the development of lymphoma.
  • [MeSH-major] Lymphoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Demography. Educational Status. Female. Hodgkin Disease / epidemiology. Humans. Lymphoma, Non-Hodgkin / epidemiology. Male. Marital Status. Middle Aged. Nigeria / epidemiology. Occupations. Residence Characteristics. Sex Factors. Social Class

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17278323.001).
  • [ISSN] 1117-1936
  • [Journal-full-title] The Nigerian postgraduate medical journal
  • [ISO-abbreviation] Niger Postgrad Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


70. Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, Sehn LH, Shenkier TN, Gascoyne RD, Connors JM: Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol; 2008 Nov 10;26(32):5165-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma.
  • PURPOSE: To assess the incidence and predictive factors for development of transformed lymphoma in a population-based series of patients with follicular lymphoma (FL).
  • Transformed lymphoma was defined as the development of aggressive non-Hodgkin's lymphoma (NHL) in patients with FL.
  • Factors present at the time of initial diagnosis of indolent NHL and at transformation were analyzed for their impact on risk of transformation and subsequent outcome.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Lymphoma, Follicular / epidemiology. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Biopsy. British Columbia / epidemiology. Disease Progression. Female. Humans. Incidence. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Population Surveillance. Registries. Retrospective Studies. Risk Assessment. Risk Factors. Time Factors. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18838711.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


71. Sands NB, Tewfik MA, Hwang SY, Desrosiers M: Extranodal T-cell lymphoma of the sinonasal tract presenting as severe rhinitis: case series. J Otolaryngol Head Neck Surg; 2008 Aug;37(4):528-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal T-cell lymphoma of the sinonasal tract presenting as severe rhinitis: case series.
  • One clinical entity that mimics severe rhinitis and thus poses a particular challenge in this regard is extranodal T-cell lymphoma of the sinonasal tract.
  • Sinonasal lymphoma has a vague initial presentation that masquerades as more common, benign causes of rhinitis but progresses as a "midfacial progressive destructive lesion" and is uniformly fatal if untreated.
  • Each patient presented initially with severe rhinitis but was later diagnosed with extranodal natural killer/T-cell non-Hodgkin lymphoma of the sinonasal tract.
  • CONCLUSION: The challenge in making an early diagnosis of T-cell lymphoma of the sinonasal tract has been reaffirmed in our case series.
  • [MeSH-major] Lymphoma, T-Cell / diagnosis. Paranasal Sinus Neoplasms / diagnosis
  • [MeSH-minor] Adult. Combined Modality Therapy. Diagnosis, Differential. Facial Pain / pathology. Female. Humans. Male. Middle Aged. Nasal Obstruction / pathology. Rhinitis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19128588.001).
  • [ISSN] 1916-0216
  • [Journal-full-title] Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
  • [ISO-abbreviation] J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


72. Alinari L, Castellucci P, Elstrom R, Ambrosini V, Stefoni V, Nanni C, Berkowitz A, Tani M, Farsad M, Franchi R, Fanti S, Zinzani PL: 18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. Leuk Lymphoma; 2006 Oct;47(10):2096-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma.
  • To evaluate the sensitivity of 18-fluoro-2-deoxyglucose (18F-FDG) positron emission tomography (PET) in patients with mucosa-associated lymphoid tissue (MALT) lymphoma.
  • A total of 32 patients with a histological diagnosis of extra-nodal MALT lymphoma were referred to the PET Centers in the last 2 years (2003 - 2004) and scanned with 18F-FDG-PET following standard procedures.
  • The data show that 18FDG-PET is a useful diagnostic tool in order to stage, restage or monitor disease in patients with extra-nodal MALT lymphoma.
  • [MeSH-major] Fluorodeoxyglucose F18. Lymphoma / diagnosis. Lymphoma / radionuclide imaging. Lymphoma, B-Cell, Marginal Zone / diagnosis. Positron-Emission Tomography / methods. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Image Processing, Computer-Assisted. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / radionuclide imaging. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Oct;47(10):2008-10 [17071468.001]
  • (PMID = 17071482.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


73. Josting A, Nogová L, Franklin J, Glossmann JP, Eich HT, Sieber M, Schober T, Boettcher HD, Schulz U, Müller RP, Diehl V, Engert A: Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol; 2005 Mar 1;23(7):1522-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group.
  • PURPOSE: To evaluate treatment outcome and prognostic factors in patients with refractory or first relapsed Hodgkin's disease (HD) treated with salvage radiotherapy (SRT) alone.
  • PATIENTS AND METHODS: From 4,754 patients registered in the database of the German Hodgkin Study Group from 1988 to 1999, 624 patients were identified with progressive disease (n = 202), or with early (n = 170) or late (n = 252) relapsed HD.
  • [MeSH-major] Hodgkin Disease / radiotherapy. Salvage Therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Cyclophosphamide / therapeutic use. Dacarbazine / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Male. Middle Aged. Prednisone / therapeutic use. Procarbazine / therapeutic use. Radiotherapy / adverse effects. Retrospective Studies. Survival Rate. Treatment Failure. Vinblastine / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15632410.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol; BEACOPP protocol; COPP protocol
  •  go-up   go-down


74. Engert A, Griskevicius L, Zyuzgin Y, Lubenau H, del Giglio A: XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk Lymphoma; 2009 Mar;50(3):374-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy.
  • The aim of the present study was to investigate a new G-CSF, XM02, in comparison to filgrastim in terms of safety and efficacy in the prevention of chemotherapy-induced neutropenia in non-Hodgkin-lymphoma (NHL).
  • Treatment with XM02 is as beneficial as filgrastim in ameliorating severe neutropenia and FN in patients with NHL receiving chemotherapy.
  • [MeSH-major] Granulocyte Colony-Stimulating Factor / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Neutropenia / prevention & control
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug-Related Side Effects and Adverse Reactions. Female. Fever / drug therapy. Fever / prevention & control. Filgrastim. Humans. Male. Middle Aged. Recombinant Proteins. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. Filgrastim .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19347726.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


75. Kennedy GA, Restall J, Morris K, Ravi Kumar A: Post-therapy calcification can result in false-positive fluorodeoxyglucose positron emission tomography scans in patients with non-Hodgkin's lymphoma. Leuk Lymphoma; 2010 Feb;51(2):348-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-therapy calcification can result in false-positive fluorodeoxyglucose positron emission tomography scans in patients with non-Hodgkin's lymphoma.
  • [MeSH-minor] Adult. False Positive Reactions. Fluorodeoxyglucose F18. Humans. Lymphoma, Non-Hodgkin / drug therapy. Male. Young Adult

  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038215.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


76. Safi S, Kassmaoui H, Hassikou H, Alami M, Homadi A, Tabache F, Baaj M, Hadri L: [Primary non-Hodgkin's lymphoma of the adrenals. A case report]. Ann Endocrinol (Paris); 2007 Jun;68(2-3):208-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary non-Hodgkin's lymphoma of the adrenals. A case report].
  • [Transliterated title] Lymphome malin non hodgkinien primitif de la surrénale. A propos d'un cas.
  • Bilateral primary non-Hodgkin's lymphoma (NHL) of the adrenals is uncommon.
  • We report a case of large diffuse B-cell adrenal lymphoma discovered in a 40-year-old woman presenting bilateral lumbar pain.
  • Percutaneous CT-guided biopsy of the adrenal and search for extension revealed primary bilateral adrenal lymphoma.
  • The diagnosis of primary adrenal non-Hodgkin lymphoma should be investigated in patients with a rapidly growing bilateral adrenal mass associated with adrenal insufficiency.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Prednisone / therapeutic use. Shock, Septic / etiology. Tomography, X-Ray Computed. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17531185.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


77. van der Kaaij MA, van Echten-Arends J, Simons AH, Kluin-Nelemans HC: Fertility preservation after chemotherapy for Hodgkin lymphoma. Hematol Oncol; 2010 Dec;28(4):168-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility preservation after chemotherapy for Hodgkin lymphoma.
  • Treatment for Hodgkin lymphoma can negatively affect fertility.
  • This review summarizes data on fertility after chemotherapy in adult patients.
  • Non-alkylating chemotherapy, like ABVD, is much less harmful: one-third of male patients develop transient azoospermia, and almost no female patients experience ovarian failure.
  • For females with a partner, IVF followed by embryo cryopreservation is a widely available method, but this necessitates postponement of lymphoma therapy for at least a month.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Fertility / drug effects. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adult. Azoospermia / chemically induced. Cryopreservation / methods. Female. Humans. Male. Ovarian Diseases / chemically induced

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 John Wiley & Sons, Ltd.
  • [CommentIn] Hematol Oncol. 2011 Mar;29(1):52; author reply 53 [20535782.001]
  • (PMID = 20232475.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


78. Pfreundschuh M, Zwick C, Zeynalova S, Dührsen U, Pflüger KH, Vrieling T, Mesters R, Mergenthaler HG, Einsele H, Bentz M, Lengfelder E, Trümper L, Rübe C, Schmitz N, Loeffler M, German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL): Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol; 2008 Mar;19(3):545-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
  • BACKGROUND: The addition of etoposide to combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone [etoposide to combination chemotherapy with cyclophosphamide, vincristine and prednisone (CHOEP)] improved outcome of young patients with good-prognosis aggressive lymphoma.
  • PATIENTS AND METHODS: Intention-to-treat analysis of 389 young (18-60 years) patients with good-prognosis (age-adjusted International Prognostic Index = 0, 1) aggressive lymphoma randomized to CHOEP-21 (n = 194) or high CHOEP (n = 195).

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18065407.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


79. Czuczman MS, Koryzna A, Mohr A, Stewart C, Donohue K, Blumenson L, Bernstein ZP, McCarthy P, Alam A, Hernandez-Ilizaliturri F, Skipper M, Brown K, Chanan-Khan A, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-Lopez A, Bernstein SH: Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol; 2005 Feb 1;23(4):694-704
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma.
  • PURPOSE: To evaluate the safety and efficacy of fludarabine plus rituximab in treatment-naive or relapsed patients with low-grade and/or follicular non-Hodgkin's lymphoma.
  • CONCLUSION: Rituximab plus fludarabine was well tolerated and associated with an excellent complete response rate, including molecular remissions, in patients with low-grade or follicular lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Follicular / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Female. Flow Cytometry. Genes, bcl-2. Humans. Male. Middle Aged. Rituximab. T-Lymphocyte Subsets / immunology

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15681517.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


80. Heredia F, Bravo M, Pierotic M, Majlis A, Carmona L: Neoadjuvant combined chemotherapy followed by external whole pelvic irradiation in two cases of primary extranodal non-Hodgkin's lymphoma of the uterine cervix. Gynecol Oncol; 2005 Apr;97(1):285-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant combined chemotherapy followed by external whole pelvic irradiation in two cases of primary extranodal non-Hodgkin's lymphoma of the uterine cervix.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Leucovorin / administration & dosage. Methotrexate / administration & dosage. Neoadjuvant Therapy. Prednisone / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15790479.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol; MTX-CHOP protocol
  •  go-up   go-down


81. Gül U, Kiliç A, Demirel O, Gönül M, Külcü Cakmak S, Demiriz M: Non-Hodgkin's lymphoma associated with leiomyomatosis presenting with intense pruritus. Acta Derm Venereol; 2007;87(2):171-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma associated with leiomyomatosis presenting with intense pruritus.
  • [MeSH-major] Leiomyomatosis / pathology. Lymphoma, Non-Hodgkin / pathology. Pruritus / pathology
  • [MeSH-minor] Adult. Female. Humans

  • MedlinePlus Health Information. consumer health - Itching.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17340029.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Norway
  •  go-up   go-down


82. Crocchiolo R, Canevari C, Assanelli A, Lunghi F, Tassara M, Stanghellini ML, Clerici D, Landoni C, Servida P, Bernardi M, Peccatori J, Ferreri A, Gianolli L, Bordignon C, Caligaris-Cappio F, Ciceri F, Fazio F: Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation. Leuk Lymphoma; 2008 Apr;49(4):727-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation.
  • We evaluated the prognostic role of 18FDG-PET performed before ASCT in patients affected by lymphoma who underwent high-dose chemotherapy followed by ASCT as first-line treatment for high-risk disease or as second-line or more for relapsed or refractory disease.
  • We retrospectively analyzed 53 consecutive patients, 14 with Hodgkin Lymphoma (HL) and 39 with non-Hodgkin Lymphoma (NHL), treated between February 1999 and October 2006 at our institution, who had a pre-ASCT FDG-PET (pPET) evaluation.
  • After a median follow-up of 31 months (range: 8-91), 7 out of 16 pPET+ patients and 10 out of 37 pPET- patients experienced lymphoma relapse.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Positron-Emission Tomography / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fluorodeoxyglucose F18. Humans. Middle Aged. Preoperative Care. Prognosis. Recurrence. Retrospective Studies. Survival Rate. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18398740.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


83. Ribrag V, Vanel D, Leboulleux S, Lumbroso J, Couanet D, Bonniaud G, Aupérin A, Masson F, Bosq J, Edeline V, Fermé C, Pigneur F, Schlumberger M: Prospective study of bone marrow infiltration in aggressive lymphoma by three independent methods: whole-body MRI, PET/CT and bone marrow biopsy. Eur J Radiol; 2008 May;66(2):325-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective study of bone marrow infiltration in aggressive lymphoma by three independent methods: whole-body MRI, PET/CT and bone marrow biopsy.
  • PURPOSE: Initial lymphoma staging requires bone marrow assessment in aggressive lymphomas.
  • Bone marrow lymphoma infiltration is routinely assessed by bone marrow biopsy (BMB), considered as the "gold standard".
  • METHODS: Patients with newly diagnosed aggressive lymphoma were evaluated by BMB, MRI and PET/CT.
  • Among these nine patients, two with an iliac crest lesion detected by both MRI and PET/CT had bone marrow involvement with large-cell lymphoma on histological examination.
  • The other patients had bone marrow without large-cell lymphoma involvement.
  • In all cases, after lymphoma therapy bone marrow involvement regressed on histological examination, PET and MRI.
  • CONCLUSION: These preliminary results suggest that non-invasive morphological procedures could be superior to BMB for bone marrow assessment in aggressive lymphomas.
  • [MeSH-major] Bone Marrow Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Fluorodeoxyglucose F18. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prednisone / therapeutic use. Prospective Studies. Radiopharmaceuticals. Sensitivity and Specificity. Tomography, Emission-Computed. Tomography, X-Ray Computed. Vincristine / therapeutic use. Whole Body Imaging

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17651934.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


84. Quinlan SC, Landgren O, Morton LM, Engels EA: Hodgkin lymphoma among US solid organ transplant recipients. Transplantation; 2010 Nov 15;90(9):1011-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma among US solid organ transplant recipients.
  • BACKGROUND: To assess the risk and identify risk factors of Hodgkin lymphoma (HL) in solid organ transplant recipients.
  • [MeSH-major] Hodgkin Disease / epidemiology. Organ Transplantation / adverse effects
  • [MeSH-minor] Adolescent. Adult. Child. Cohort Studies. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Proportional Hazards Models. Retrospective Studies. Risk Factors. Time Factors. United States


85. Morabito F, Stelitano C, Luminari S, Mammi C, Marcheselli L, Callea V, Gentile M, Polimeno G, Merli F, Molica S, Gobbi P, Angrilli F, Brugiatelli M, Federico M: The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL). Bone Marrow Transplant; 2006 Feb;37(3):283-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL).
  • GISL recently conducted an exhaustive survey of 1078 patients with Hodgkin's Lymphoma (HL) enrolled between 1988 and 2002 in different prospective trials.
  • [MeSH-major] Data Collection. Hodgkin Disease / mortality. Hodgkin Disease / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Salvage Therapy / methods. Salvage Therapy / mortality. Survival Rate. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16327815.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


86. Halilbasić A, Mesic E, Cikusić E, Arnautović A: [Non Hodgkin lymphoma in the North-East Bosnia--changes in biological aggressiveness and primary presentation of the disease]. Med Arh; 2006;60(6 Suppl 2):78-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non Hodgkin lymphoma in the North-East Bosnia--changes in biological aggressiveness and primary presentation of the disease].
  • [Transliterated title] Non Hodgkin limfom u Sjeveroistoinoj Bosni--promjene u bioloskoj agresivnosti i nacinu primarne prezentacije.
  • INTRODUCTION: NHL are the group of lymphoproliferative neoplasms which incidence is in constant increase.
  • The aim of the paper is the analysis of the immunophenotypes, clinical distribution and ways of primary presentation and biological aggressiveness of NHL in the North-East Bosnia.
  • METHODS: Two hundred and twenty-eight patients with pathohistologically proved NHL are analysed in the paper.
  • The tested group consisted of 142 patients with diagnosed NHL in the period between 1998 and 2002, and the control group consisted of 86 patients whose NHL was proved in the period between 1987 and 1991.
  • These factors were analysed: immunophenotype NHL by immunohistochemical method of indirect three-stage immunoperoxidase with streptovidin, the type of NHL, the degree of biological aggressiveness of NHL, the way of primary presentation and the clinical phases of distribution of the disease according to the age, sex, profession and the habitat (urban or rural) of the patients.
  • RESULTS: The total number of patients with NHL in the North-East Bosnia was quite bigger in the test group than in the control group with the incidence of 2.6/100,000 inhabitants in 1989, and 6.91/100,000 inhabitants in 2002.
  • Diffuse Large Cell Lymphoma (DLCL) was dominant in the test group with total of 73 patients (51%), and Small Cell Lymphoma was dominant in the control group with total of 33 patients (38%).
  • Statistically significant increase of both DLCL and MALT lymphoma is found in the test group (p < 0.025), and the most frequent were patients with IV-B (18%), I-AE (15%) and II-BE (12%) clinical stadium, while in the control group the most frequent number of patients was in the clinical studia III-B (19%), II-B (14%) and IV-B (14%).
  • In the test group there was a significant increase of aggressive lymphoma in both men and women (p < 0.01).
  • DISCUSSION: In recent years, all NHL studies have shown an increase of the incidence in patients, especially in older age while the increase is not found only in infants.
  • In our study the highest percentage of the incidence of NHL occurs in patients who are 55 and older that exactly matches the literature date.
  • In the test group the number of MALT and DLCL lymphoma located in stomach is in increase.
  • In the last few years the dominant type of NHL worldwide is DLCL.
  • The continuous increase of patients with aggressive NHL in the recent years has been noticed especially Lukavac, Tuzla and Zivinice.
  • CONCLUSION: The incidence of NHL in the region of the North East Bosnia follows the world trend of the general increase of the NHL incidence including the significant increase in number of aggressive lymphoma.
  • The frequency of DLCL and MALT lymphoma is evidently in increase.
  • B phenotype of NHL is predominant in both periods of testing.
  • [MeSH-major] Lymphoma, Non-Hodgkin
  • [MeSH-minor] Adolescent. Adult. Aged. Bosnia and Herzegovina / epidemiology. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18172989.001).
  • [Journal-full-title] Medicinski arhiv
  • [ISO-abbreviation] Med Arh
  • [Language] bos
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


87. Bangerter M, Brudler O, Heinrich B, Griesshamnuer M: Fine needle aspiration cytology and flow cytometry in the diagnosis and subclassification of non-Hodgkin's lymphoma based on the World Health Organization classification. Acta Cytol; 2007 May-Jun;51(3):390-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology and flow cytometry in the diagnosis and subclassification of non-Hodgkin's lymphoma based on the World Health Organization classification.
  • OBJECTIVE: To determine the usefulness of fine needle aspiration cytology (FNAC) in combination with flow cytometry on the new World Health Organization (WHO) classification of malignant lymphoma.
  • Both methods were classified according to the new WHO classification of malignant lymphoma.
  • CONCLUSION: The combination of FNAC and flow cytometry obtained by FNAC can distinguish between benign and malignant lymphoid infiltrates and support a diagnosis of lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / classification. Lymphoma, Non-Hodgkin / pathology. World Health Organization
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Female. Flow Cytometry. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / classification. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymph Nodes / pathology. Lymphoma, B-Cell / classification. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / pathology. Lymphoma, Mantle-Cell / classification. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / pathology. Male. Middle Aged. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17536541.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Willett EV, Morton LM, Hartge P, Becker N, Bernstein L, Boffetta P, Bracci P, Cerhan J, Chiu BC, Cocco P, Dal Maso L, Davis S, De Sanjose S, Smedby KE, Ennas MG, Foretova L, Holly EA, La Vecchia C, Matsuo K, Maynadie M, Melbye M, Negri E, Nieters A, Severson R, Slager SL, Spinelli JJ, Staines A, Talamini R, Vornanen M, Weisenburger DD, Roman E, Interlymph Consortium: Non-Hodgkin lymphoma and obesity: a pooled analysis from the InterLymph Consortium. Int J Cancer; 2008 May 1;122(9):2062-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin lymphoma and obesity: a pooled analysis from the InterLymph Consortium.
  • Nutritional status is known to alter immune function, a suspected risk factor for non-Hodgkin lymphoma (NHL).
  • To investigate whether long-term over, or under, nutrition is associated with NHL, self-reported anthropometric data on weight and height from over 10,000 cases of NHL and 16,000 controls were pooled across 18 case-control studies identified through the International Lymphoma Epidemiology Consortium.
  • Severe obesity, defined as BMI of 40 kg m(-2) or more, was not associated with NHL overall (pooled OR = 1.00, 95% confidence interval (CI) 0.70-1.41) or the majority of NHL subtypes.
  • An excess was however observed for diffuse large B-cell lymphoma (pooled OR = 1.80, 95% CI 1.24-2.62), although not all study-specific ORs were raised.
  • There was little suggestion of increasing ORs for NHL or its subtypes with every 5 kg m(-2) rise in BMI above 18.5 kg m(-2).
  • In summary, whilst we conclude that there is no evidence to support the hypothesis that obesity is a determinant of all types of NHL combined, the association between severe obesity and diffuse large B-cell lymphoma may warrant further investigation.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Obesity.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Obesity.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • [Cites] J Epidemiol Community Health. 2001 Aug;55(8):534-6 [11449009.001]
  • [Cites] Stat Med. 2002 Jun 15;21(11):1539-58 [12111919.001]
  • [Cites] Obes Rev. 2001 May;2(2):131-40 [12119664.001]
  • [Cites] Public Health Nutr. 2002 Aug;5(4):561-5 [12186665.001]
  • [Cites] Am J Epidemiol. 2002 Sep 15;156(6):527-35 [12226000.001]
  • [Cites] Int J Cancer. 2003 Apr 20;104(4):522-4 [12584752.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1625-38 [12711737.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 20;91(20):1751-8 [10528026.001]
  • [Cites] Cancer Causes Control. 2001 Jan;12(1):13-21 [11227921.001]
  • [Cites] World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253 [11234459.001]
  • [Cites] Am J Epidemiol. 2004 Feb 1;159(3):259-68 [14742286.001]
  • [Cites] Cancer Causes Control. 2004 Feb;15(1):35-43 [14970733.001]
  • [Cites] Int J Cancer. 2004 Jun 20;110(3):380-5 [15095303.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):779-86 [15159310.001]
  • [Cites] Leuk Res. 2004 Jul;28(7):713-24 [15158093.001]
  • [Cites] Am J Epidemiol. 2004 Sep 15;160(6):566-75 [15353417.001]
  • [Cites] Cancer Causes Control. 2004 Oct;15(8):771-80 [15456990.001]
  • [Cites] J Natl Cancer Inst. 1978 Jan;60(1):89-92 [272469.001]
  • [Cites] J Natl Cancer Inst. 1985 Jan;74(1):43-51 [3855486.001]
  • [Cites] Leuk Res. 1989;13(6):465-72 [2770331.001]
  • [Cites] Eur J Cancer. 1994;30A(3):344-50 [8204357.001]
  • [Cites] Am J Epidemiol. 1995 Aug 15;142(4):371-82 [7625401.001]
  • [Cites] World Health Organ Tech Rep Ser. 1995;854:1-452 [8594834.001]
  • [Cites] Am J Epidemiol. 1999 Aug 15;150(4):375-89 [10453814.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):210-8 [15687364.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):925-33 [15824165.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 1;97(11):860-1 [15928310.001]
  • [Cites] Lancet Oncol. 2005 Jul;6(7):469-76 [15992695.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4742-54 [16034050.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 3;97(15):1154-7 [16077074.001]
  • [Cites] Br J Cancer. 2005 Oct 3;93(7):811-6 [16160698.001]
  • [Cites] Cancer Causes Control. 2005 Dec;16(10):1203-14 [16215871.001]
  • [Cites] Br J Cancer. 2005 Oct 31;93(9):1062-7 [16234822.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):458-66 [16049963.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):27-38 [16389181.001]
  • [Cites] Int J Cancer. 2006 May 1;118(9):2298-302 [16331621.001]
  • [Cites] Carcinogenesis. 2006 Jul;27(7):1391-7 [16400189.001]
  • [Cites] Cancer Causes Control. 2006 Sep;17(7):901-9 [16841257.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):378-84 [16819547.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2348-54 [17164355.001]
  • [Cites] Am J Epidemiol. 2007 Jan 1;165(1):44-52 [17041129.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3479-88 [17185468.001]
  • [Cites] Cancer Causes Control. 2007 Aug;18(6):677-85 [17484069.001]
  • [Cites] Obes Rev. 2007 Jul;8(4):307-26 [17578381.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1564-70 [17443495.001]
  • [Cites] Am J Epidemiol. 2007 Sep 15;166(6):697-708 [17596266.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2767-75 [17722095.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]
  • [CommentIn] Int J Cancer. 2008 Jul 15;123(2):490; author reply 491-2 [18449886.001]
  • (PMID = 18167059.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / N01 PC067009; United States / NCI NIH HHS / CN / N01 PC067009-025; United States / NCI NIH HHS / PC / N01 PC067010; United States / NCI NIH HHS / PC / PC67009; United States / NCI NIH HHS / CA / CA50850; United States / NCI NIH HHS / PC / PC67008; United States / NCI NIH HHS / CA / 5R01 CA69269-02; United States / NCI NIH HHS / PC / N01 PC067008; United States / NCI NIH HHS / CA / CA92153; United States / NCI NIH HHS / CA / R01 CA051086-03; United States / Intramural NIH HHS / / ZIA CP010170-13; None / None / / N01 PC065064; United States / NCI NIH HHS / PC / PC71105; United States / NCI NIH HHS / PC / N01 PC065064; United States / NCI NIH HHS / PC / PC67010; United States / NCI NIH HHS / CA / R01 CA092153; United States / NCI NIH HHS / PC / PC65064; United States / NCI NIH HHS / CA / CA51086; United States / NCI NIH HHS / CA / R01 CA051086; United States / NCI NIH HHS / CA / R01 CA069269
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS547972; NLM/ PMC3928289
  •  go-up   go-down


89. Worrillow LJ, Smith AG, Scott K, Andersson M, Ashcroft AJ, Dores GM, Glimelius B, Holowaty E, Jackson GH, Jones GL, Lynch CF, Morgan G, Pukkala E, Scott D, Storm HH, Taylor PR, Vyberg M, Willett E, Travis LB, Allan JM: Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma. J Med Genet; 2008 Mar;45(3):142-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma.
  • BACKGROUND AND OBJECTIVE: Methylating agents are effective chemotherapy agents for Hodgkin lymphoma, but are associated with the development of second primary cancers.
  • METHODS: 133 patients who developed cancer following chemotherapy and/or radiotherapy (n = 133), 420 patients diagnosed with de novo myeloid leukaemia, 242 patients diagnosed with primary Hodgkin lymphoma, and 1177 healthy controls were genotyped for the MLH1 -93 polymorphism by allelic discrimination polymerase chain reaction (PCR) and restriction fragment length polymorphism assay.
  • n = 15) after methylating chemotherapy for Hodgkin lymphoma compared to patients without previous methylating exposure (t-AML, 30.4%, n = 69; breast cancer patients, 27.2%, n = 22).
  • CONCLUSIONS: These data support the hypothesis that the common polymorphism at position -93 in the core promoter of MLH1 defines a risk allele for the development of cancer after methylating chemotherapy for Hodgkin lymphoma.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Antineoplastic Agents, Alkylating / adverse effects. Hodgkin Disease / drug therapy. Hodgkin Disease / genetics. Neoplasms, Second Primary / etiology. Nuclear Proteins / genetics. Polymorphism, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Alleles. Base Sequence. Case-Control Studies. DNA Methylation. DNA Primers / genetics. DNA Repair / genetics. Female. Humans. Leukemia, Myeloid, Acute / chemically induced. Leukemia, Myeloid, Acute / etiology. Leukemia, Myeloid, Acute / genetics. Male. Middle Aged. Promoter Regions, Genetic. Risk Factors

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827853591 for PMID:17959715 [PharmGKB] .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3440-6 [12668650.001]
  • [Cites] Int J Cancer. 2004 Nov 20;112(4):678-82 [15382050.001]
  • [Cites] Gene. 2003 Mar 13;306:57-65 [12657467.001]
  • [Cites] JAMA. 2003 Jul 23;290(4):465-75 [12876089.001]
  • [Cites] Nature. 1969 Jul 12;223(5202):206-7 [5791738.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum Suppl. 1987;7:1-440 [3482203.001]
  • [Cites] Biochemistry. 1994 Apr 26;33(16):4787-93 [8161538.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Mar 24;256(3):488-94 [10080925.001]
  • [Cites] J Natl Cancer Inst. 2006 Jan 4;98(1):15-25 [16391368.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 1;98(3):215-8 [16449681.001]
  • [Cites] Chem Rev. 2006 Feb;106(2):302-23 [16464007.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):22674-83 [16772289.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1636-40 [16985024.001]
  • [Cites] Epidemiology. 2007 Jan;18(1):130-6 [17099321.001]
  • [Cites] J Natl Cancer Inst. 2007 Mar 21;99(6):463-74 [17374836.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1489-97 [17372278.001]
  • [Cites] Br J Cancer. 1999 Dec;81(7):1228-33 [10584886.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11592-7 [11553769.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 6;94(3):182-92 [11830608.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3484-94 [12177110.001]
  • [Cites] Mutagenesis. 2002 Nov;17(6):483-7 [12435845.001]
  • (PMID = 17959715.001).
  • [ISSN] 1468-6244
  • [Journal-full-title] Journal of medical genetics
  • [ISO-abbreviation] J. Med. Genet.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA CP010131-18
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antineoplastic Agents, Alkylating; 0 / DNA Primers; 0 / MLH1 protein, human; 0 / Nuclear Proteins
  • [Other-IDs] NLM/ NIHMS579369; NLM/ PMC4022773
  •  go-up   go-down


90. Bilora F, Pietrogrande F, Petrobelli F, Polato G, Pomerri F, Muzzio PC: Is radiation a risk factor for atherosclerosis? An echo-color Doppler study on Hodgkin and non-Hodgkin patients. Tumori; 2006 Jul-Aug;92(4):295-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is radiation a risk factor for atherosclerosis? An echo-color Doppler study on Hodgkin and non-Hodgkin patients.
  • AIMS AND BACKGROUND: The aim of the present paper was to study the role of irradiation in the atherosclerotic process in patients affected by Hodgkin and non-Hodgkin lymphoma.
  • METHODS: We studied 84 subjects, 42 with Hodgkin or non-Hodgkin disease and 42 controls.
  • [MeSH-major] Atherosclerosis / diagnostic imaging. Atherosclerosis / etiology. Hodgkin Disease / radiotherapy. Lymphoma, Non-Hodgkin / radiotherapy. Radiation Injuries / complications. Ultrasonography, Doppler, Color
  • [MeSH-minor] Adult. Aorta, Abdominal / radiation effects. Carotid Arteries / radiation effects. Female. Femoral Artery / radiation effects. Humans. Male. Middle Aged. Radiotherapy / adverse effects. Tunica Intima / radiation effects. Tunica Media / radiation effects

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Tumori. 2007 Mar-Apr;93(2):232; author reply 232 [17557581.001]
  • (PMID = 17036519.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Lerut E, Kuypers DR, Van Damme B: Polyomavirus interstitial nephritis and concurrent post-transplant lymphoma in a renal allograft: coincidence or more? Transpl Int; 2005 Nov;18(11):1304-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polyomavirus interstitial nephritis and concurrent post-transplant lymphoma in a renal allograft: coincidence or more?
  • We describe a case of an Epstein-Barr virus (EBV)-negative post-transplant large B-cell non-Hodgkin lymphoma located in the renal allograft, spleen, liver and left inguinal lymph node of a renal recipient and accompanied by a simultaneous polyomavirus-associated nephropathy.
  • [MeSH-major] Kidney Transplantation. Lymphoma, B-Cell / complications. Lymphoma, Large B-Cell, Diffuse / complications. Nephritis / virology. Polyomavirus Infections / complications. Tumor Virus Infections / complications
  • [MeSH-minor] Adult. Humans. Male. Postoperative Complications / virology

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16221164.001).
  • [ISSN] 0934-0874
  • [Journal-full-title] Transplant international : official journal of the European Society for Organ Transplantation
  • [ISO-abbreviation] Transpl. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


92. Ohmachi K, Ando K, Ogura M, Uchida T, Itoh K, Kubota N, Ishizawa K, Yamamoto J, Watanabe T, Uike N, Choi I, Terui Y, Usuki K, Nagai H, Uoshima N, Tobinai K, Japanese Bendamustine Lymphoma Study Group: Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci; 2010 Sep;101(9):2059-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
  • Bendamustine is a unique cytotoxic agent that has demonstrated efficacy in the treatment of indolent B-cell non-Hodgkin lymphomas (B-NHLs).
  • In this multicenter phase II trial, the efficacy and safety of bendamustine were evaluated in Japanese patients with relapsed or refractory indolent B-NHL or mantle-cell lymphoma (MCL).
  • Fifty-eight patients with indolent B-NHL and 11 with MCL were enrolled.
  • By IWRC, bendamustine produced an ORR of 91% (95% confidence interval [CI], 82-97%; 90% and 100% in patients with indolent B-NHL and MCL, respectively), with a CR rate of 67% (95% CI, 54-78%).
  • Estimated PFS rates at 1 year were 70% and 90% among indolent B-NHL and MCL patients, respectively.
  • Common non-hematologic toxicities included mild gastrointestinal events and fatigue.
  • These results demonstrate the high efficacy and tolerability of single-agent bendamustine in relapsed patients with indolent B-NHL or MCL histologies.
  • [MeSH-major] Lymphoma, B-Cell / drug therapy. Lymphoma, Mantle-Cell / drug therapy. Nitrogen Mustard Compounds / therapeutic use
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Bendamustine Hydrochloride. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Humans. Kaplan-Meier Estimate. Leukopenia / chemically induced. Male. Middle Aged. Nausea / chemically induced. Neoplasm Staging. Neutropenia / chemically induced. Pneumonia / chemically induced. Recurrence. Treatment Outcome. Vomiting / chemically induced


93. Pedersen LM, Klausen TW, Davidsen UH, Johnsen HE: Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma. Ann Hematol; 2005 Aug;84(8):510-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma.
  • Several lines of evidence suggest that serum levels of interleukin (IL)-6 and vascular endothelial growth factor (VEGF) are independent indicators of long-term outcome in non-Hodgkin's lymphoma (NHL), but the clinical impact of early serial monitoring of these cytokines has not been reported.
  • Serum samples from 64 newly diagnosed patients with aggressive NHL were obtained before the first cycle of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and then weekly until the second cycle was given.
  • [MeSH-major] Interleukin-6 / blood. Lymphoma, Non-Hodgkin / diagnosis. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Inflammation / blood. Male. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Prednisone / therapeutic use. Prognosis. Survival Analysis. Treatment Outcome. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15834569.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / Vascular Endothelial Growth Factor A; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


94. Vladareanu AM, Ciufu C, Neagu AM, Onisai M, Bumbea H, Vintilescu AM, Dobrea C, Arama V, Mihailescu R, Arama S: The impact of hepatitis viruses on chronic lymphoproliferative disorders--preliminary results. J Med Life; 2010 Jul-Sep;3(3):320-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histological types of CLD: B-cell non-Hodgkin's lymphoma--in 28/41 (68.29%) patients, T-cell non-Hodgkin's lymphoma--2/41 (4.87%) patients, Hodgkin's lymphoma--2/41 (4.87%), chronic lymphocytic leukemia--7/41 (17.07%), Waldenström disease--2/41 (4.87%) patients.
  • Regarding the type of CLD, 19/41 (46.34%) of the patients have an aggressive type of CLD and 22/41 (53.65%) a non-aggressive type of CLD.
  • Within HBV infection subgroup 9/14 (64.28%) patients have an aggressive type of CLD and 5/14 (35,71%) patients have a non-aggressive type, whereas within the group with HCV infection we found a different distribution: 9/24 (37,5%) patients with aggressive type and 15/24 (62.5%) with non-aggressive type of CLD.
  • The clinical parameters monitored were: B signs were present in 19/41 (43.34%) patients, the superficial or profound adenopathies--were found in 29/41 (70,73%) patients, hepatomegaly--in 38/41 (92,68%) patients, splenomegaly--in 21/41 (51.21%) patients, extra-nodal involvements in 10/41 (24,39%) patients and most frequent in the non-aggressive type of CLD--6/10 (60%) patients.
  • The hematological and biochemical parameters were: the presence of anemia and thrombocytopenia--found in a small number of patients; lymphocytosis--positive in 33/41 (80.48%) patients, most with HCV infection and non-aggressive type of disease, the presence of autoimmune hemolytic anemia--in 4/41 (9.75%) patients, cryoglobulins--8/41 (19.51%) patients, all with HCV infection; also the liver function was monitored.
  • A strong association between B-cell chronic lymphoproliferative disorders and hepatitis viral infection B, C, D was revealed, the most frequent being the C hepatitis virus, associated with the non-aggressive type of CLD, extra-nodal involvement, splenomegaly, lymphocytosis, cryoglobulins, cytolysis and colestasis.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hepatitis B, Chronic / complications. Hepatitis C, Chronic / complications. Hepatitis D, Chronic / complications. Humans. Lymphoma, Non-Hodgkin / etiology. Male. Middle Aged. Prospective Studies. Retrospective Studies. Romania

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 1999 Dec;10(12):1419-32 [10643532.001]
  • [Cites] Curr Oncol Rep. 2000 Mar;2(2):172-5 [11122840.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3745-9 [11739181.001]
  • [Cites] Am J Gastroenterol. 2002 Jul;97(7):1802-6 [12135039.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Br J Haematol. 1994 Oct;88(2):392-4 [7803287.001]
  • [Cites] Ann Intern Med. 1996 Jan 1;124(1 Pt 1):31-4 [7503475.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Blood. 1997 Jul 15;90(2):776-82 [9226178.001]
  • [Cites] Leuk Lymphoma. 1997 Jun;26(1-2):127-30 [9250797.001]
  • [Cites] J Hepatol. 1998 Jan;28(1):34-9 [9537861.001]
  • [Cites] Am J Clin Pathol. 1998 May;109(5):600-9 [9576580.001]
  • [Cites] Clin Lab Haematol. 1998 Apr;20(2):107-10 [9681221.001]
  • [Cites] Blood. 2005 Jan 1;105(1):74-6 [15353484.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:375-80 [17124086.001]
  • [Cites] Ann Oncol. 2007 Feb;18(2):346-50 [17071937.001]
  • (PMID = 20945824.001).
  • [ISSN] 1844-122X
  • [Journal-full-title] Journal of medicine and life
  • [ISO-abbreviation] J Med Life
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Other-IDs] NLM/ PMC3019001
  •  go-up   go-down


95. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro-Murillo AM, Mocroft A, Bonnet F, Clifford G, Karafoulidou A, Miro JM, Lundgren J, Chene G, Egger M: Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Antivir Ther; 2009;14(8):1065-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study.
  • BACKGROUND: Incidence and risk factors of HIV-associated non-Hodgkin's lymphoma (NHL) are not well defined in the era of combination antiretroviral therapy (cART).
  • METHODS: A total of 56,305 adult HIV type-1 (HIV-1)-infected patients who started cART in 1 of 22 prospective studies in Europe were included.
  • Weibull random effects models were used to estimate hazard ratios (HRs) for developing systemic NHL and included CD4(+) T-cell counts and viral load as time-updated variables.
  • RESULTS: During the 212,042 person-years of follow-up, 521 patients were diagnosed with systemic NHL and 62 with primary brain lymphoma (PBL).
  • The incidence rate of systemic NHL was 463 per 100,000 person-years not on cART and 205 per 100,000 person-years in treated patients for a rate ratio of 0.44 (95% confidence interval [CI] 0.37-0.53).
  • Suppression of HIV-1 replication on cART (HR 0.60, 95% CI 0.44-0.81, comparing < or =500 with 10,000-99,999 copies/ml) and increases in CD4(+) T-cell counts (HR 0.30, 0.22-0.42, comparing > or =350 with 100-199 cells/microl) were protective; a history of Kaposi's sarcoma (HR 1.70, 1.08-2.68, compared to no history of AIDS), transmission through sex between men (HR 1.57, 1.19-2.08, compared with heterosexual transmission) and older age (HR 3.71, 2.37-5.80, comparing > or =50 with 16-29 years) were risk factors for systemic NHL.
  • CONCLUSIONS: The incidence rates of both systemic NHL and PBL were substantially reduced in patients on cART.
  • Timely initiation of therapy is key to the prevention of NHL in the era of cART.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. Brain Neoplasms / epidemiology. HIV Infections / complications. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Cohort Studies. Drug Therapy, Combination. Europe. Female. HIV-1. Humans. Incidence. Male. Risk Factors

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • HAL archives ouvertes. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 1999 Dec 15;282(23):2220-6 [10605973.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1213-24 [18955561.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] AIDS. 2001 Aug 17;15(12):1483-91 [11504980.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]
  • [Cites] Br J Cancer. 2001 Nov 2;85(9):1298-303 [11720464.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2331-6 [11895764.001]
  • [Cites] Lancet Oncol. 2003 Feb;4(2):110-9 [12573353.001]
  • [Cites] Mod Pathol. 2003 May;16(5):424-9 [12748248.001]
  • [Cites] AIDS. 2003 Jul 4;17(10):1521-9 [12824790.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2177-83 [15169806.001]
  • [Cites] Antivir Ther. 2004 Aug;9(4):631-3 [15456095.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] Am J Epidemiol. 1994 Feb 15;139(4):362-8 [8109570.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] AIDS. 1996 Feb;10(2):181-5 [8838706.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Arch Intern Med. 2005 Feb 28;165(4):416-23 [15738371.001]
  • [Cites] Leukemia. 2005 May;19(5):851-5 [15744337.001]
  • [Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264 [16020424.001]
  • [Cites] Clin Infect Dis. 2006 Feb 1;42(3):411-7 [16392091.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4123-8 [16896005.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):377-80 [17372233.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] AIDS. 2007 Sep 12;21(14):1957-63 [17721103.001]
  • [Cites] Antivir Ther. 2007;12(6):931-9 [17926647.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1350-7 [18042691.001]
  • [Cites] AIDS. 2008 Jan 11;22(2):301-6 [18097233.001]
  • [Cites] AIDS. 2008 Feb 19;22(4):489-96 [18301061.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Clin Infect Dis. 2008 Aug 1;47(3):410-7 [18582203.001]
  • [Cites] AIDS. 2008 Jul 31;22(12):1463-73 [18614870.001]
  • [Cites] JAMA. 2008 Aug 6;300(5):555-70 [18677028.001]
  • [Cites] Clin Infect Dis. 2008 Nov 1;47(9):1209-15 [18808357.001]
  • [Cites] J Clin Oncol. 2008 Oct 10;26(29):4834-42 [18591544.001]
  • [Cites] J Intern Med. 2008 Dec;264(6):537-48 [19017178.001]
  • [Cites] AIDS. 2009 Jan 2;23(1):41-50 [19050385.001]
  • [Cites] Clin Infect Dis. 2009 Mar 1;48(5):633-9 [19202627.001]
  • [Cites] AIDS. 2000 Jan 28;14(2):133-40 [10708283.001]
  • (PMID = 20032536.001).
  • [ISSN] 2040-2058
  • [Journal-full-title] Antiviral therapy
  • [ISO-abbreviation] Antivir. Ther. (Lond.)
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0700820
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  • [Other-IDs] NLM/ HALMS394577; NLM/ PMC2821596
  • [Investigator] Antinori A; Bonnet F; Boué F; Brockmeyer N; Casabona J; Costagliola D; Dronda F; Obel N; Fätkenheuer G; Fisher M; Franceschi S; Gibb D; Le Moing V; Mocroft A; Nadal D; Touloumi G; Prins M; Raffi F; Roca B; Verbon A; Wolf T; Fortuny C; Bohlius J; Chakraborty R; Clifford G; Egger M; Franceschi S; May M; Minder C; Sterne J; Zwahlen M; Ellefson M; Kjaer J; Collin F; Colin C; Weller I; Costagliola D; Ledergerber B; Lundgren J; Chene G; Touloumi G; Warszawski J; Meyer L; Dabis F; Krause MM; Goujard C; Leport C; de Wolf F; Reiss P; Porter K; Dorrucci M; Sabin C; Gibb D; Del Amo J; Obel N; Thorne C; Mocroft A; Kirk O; Staszewski S; Perez-Hoyos S; Almeda J; Antinori A; Monforte Ad; de Martino M; Brockmeyer N; Fätkenheuer G; Ramos J; Battegay M; Mussini C; Tookey P; Casabona J; Miro JM; Castagna A; de Wit S; Torti C; Teira R; Garrido M; Dedes N; Sabin C; Phillips A; Furrer H; Kirk O; Egger M; Dabis F; Newell M; Sterne J; Telenti A; Pantazis N; Lechenadec J; Jérôme F; Tran L; Balestre E; Lanoy E; Couturier F; Rispens T; Gras LA; Bhaskaran K; Sabin C; Hill T; Judd A; Duong T; Sobrino P; Obel N; Thorne C; Kjaer J; Jennings B; Pérez-Hoyos S; Almeda J; Bonfigli S; Cozzi-Lepri A; Corvasce S; Adorni F; Ridolfo AL; Paraninfo G; Ramos JT; Keiser O; Borghi V; Masters J; Ortiga B; Salpietro S; Rickenbach M; Poll B; Garrido M
  •  go-up   go-down


96. Gualco G, Weiss LM, Bacchi CE: Expression of p63 in anaplastic large cell lymphoma but not in classical Hodgkin's lymphoma. Hum Pathol; 2008 Oct;39(10):1505-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p63 in anaplastic large cell lymphoma but not in classical Hodgkin's lymphoma.
  • In malignant hematological disease, p63 expression has been reported in 22% of follicular lymphoma, about 35% of diffuse large B-cell lymphoma, 23% of chronic lymphocytic leukemia, and in some cases of blast crisis of chronic myelogenous leukemia.
  • Anaplastic large cell lymphoma is a rare disease that accounts for less than 5% of all cases of non-Hodgkin's lymphoma.
  • There is little information concerning p63 expression in this specific type of lymphoma.
  • In some cases, the morphological and phenotypic features between anaplastic large cell lymphoma and classical Hodgkin's lymphoma are similar, making this differential diagnosis challenging.
  • We studied p63 expression using a tissue microarray approach in 154 cases of anaplastic large cell lymphoma, including 38% anaplastic large cell kinase positive and 62% anaplastic large cell kinase negative, and 58 Hodgkin's lymphoma cases.
  • Sixty-eight cases of anaplastic large cell lymphoma (44%) showed p63 nuclear positivity (41% of anaplastic large cell kinase positive and 47% of anaplastic large cell kinase negative).
  • Of 130 cases of systemic-anaplastic large cell lymphoma, 42% showed p63 positivity.
  • The neoplastic cells expressed p63 in 38% of the cases of CD45-negative/anaplastic large cell kinase-negative null cell-type anaplastic large cell lymphoma, a subgroup that offers the most difficulties in the differential diagnosis with classical Hodgkin's lymphoma.
  • In contrast, none of the cases of classical Hodgkin's lymphoma demonstrated any p63 expression.
  • These results demonstrate that p63 protein expression is frequently expressed in a subset of anaplastic large cell lymphoma cases and may be used as a potential tool in the differential diagnosis between anaplastic large cell lymphoma and classical Hodgkin's lymphoma.

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2001 Jul;12(7):981-6 [11521806.001]
  • [Cites] Am J Clin Pathol. 2004 May;121(5):709-17 [15151211.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1199-206 [12368193.001]
  • [Cites] Mod Pathol. 2002 Nov;15(11):1221-6 [12429802.001]
  • [Cites] J Pathol. 2002 Dec;198(4):417-27 [12434410.001]
  • [Cites] Am J Clin Pathol. 2003 Feb;119(2):199-204 [12579989.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):223-9 [16434897.001]
  • [Cites] Haematologica. 2006 May;91(5):596-604 [16670065.001]
  • [Cites] Urology. 2004 Jun;63(6):1079-83 [15183954.001]
  • [Cites] Blood. 1985 Oct;66(4):848-58 [3876124.001]
  • [Cites] Am J Pathol. 1997 Feb;150(2):543-62 [9033270.001]
  • [Cites] Pathol Biol (Paris). 1997 Dec;45(10):898-908 [9769955.001]
  • [Cites] Mol Cell. 1998 Sep;2(3):305-16 [9774969.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3352-6 [10416592.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):237-42 [16082248.001]
  • [Cites] J Korean Med Sci. 2005 Oct;20(5):752-8 [16224147.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):1010-8 [16648862.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):300-4 [17264676.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):233-9 [17297297.001]
  • [Cites] Cell Cycle. 2007 May 2;6(9):1062-71 [17426453.001]
  • [Cites] Arch Pathol Lab Med. 2007 May;131(5):742-7 [17488159.001]
  • [Cites] Am J Clin Pathol. 2007 May;127(5):707-22 [17511113.001]
  • [Cites] J Clin Pathol. 2007 Jun;60(6):709-14 [16837628.001]
  • [Cites] Leuk Lymphoma. 2007 Jun;48(6):1127-38 [17577776.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7113-21 [14612504.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):494-501 [11839669.001]
  • (PMID = 18620733.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112217-03; United States / NCI NIH HHS / CA / R01 CA112217; United States / NCI NIH HHS / CA / 5R01CA082274; United States / NCI NIH HHS / CA / R01 CA112217-03; United States / NCI NIH HHS / CA / R01 CA082274-08; United States / NCI NIH HHS / CA / CA082274-08; United States / NCI NIH HHS / CA / R01 CA082274; United States / NCI NIH HHS / CA / U01 CA121947-016821; United States / NCI NIH HHS / CA / 5R01CA112217; United States / NCI NIH HHS / CA / CA121947-016821
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Other-IDs] NLM/ NIHMS127050; NLM/ PMC2744879
  •  go-up   go-down


97. Cozen W, Hamilton AS, Zhao P, Salam MT, Deapen DM, Nathwani BN, Weiss LM, Mack TM: A protective role for early oral exposures in the etiology of young adult Hodgkin lymphoma. Blood; 2009 Nov 5;114(19):4014-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A protective role for early oral exposures in the etiology of young adult Hodgkin lymphoma.
  • The pattern of adolescent/young adult Hodgkin lymphoma (YAHL) suggests causation by a relatively late infection with a common childhood virus, but no causal virus has been found.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Allergy. 2000 Nov;30(11):1506-10 [11069557.001]
  • [Cites] Twin Res. 2000 Mar;3(1):33-42 [10808239.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4283-97 [12036854.001]
  • [Cites] Int J Cancer. 2002 Sep 20;101(3):259-64 [12209977.001]
  • [Cites] Am J Epidemiol. 2002 Dec 1;156(11):1011-20 [12446257.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):624-30 [12594818.001]
  • [Cites] N Engl J Med. 2003 Jun 5;348(23):2313-22 [12788995.001]
  • [Cites] N Engl J Med. 2003 Oct 2;349(14):1324-32 [14523140.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3216-21 [15070705.001]
  • [Cites] Cancer Causes Control. 2004 May;15(4):387-97 [15141139.001]
  • [Cites] J Infect Dis. 2004 Jun 15;189(12):2271-81 [15181575.001]
  • [Cites] Leuk Lymphoma. 2003;44 Suppl 3:S27-32 [15202522.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1361-70 [15298959.001]
  • [Cites] J Natl Cancer Inst. 1973 Jun;50(6):1429-35 [4717560.001]
  • [Cites] Int J Cancer. 1977 May 15;19(5):595-604 [863541.001]
  • [Cites] Br Med J. 1978 Feb 11;1(6109):327-9 [623979.001]
  • [Cites] Cancer Res. 1979 Nov;39(11):4507-11 [498082.001]
  • [Cites] N Engl J Med. 1981 Jan 15;304(3):135-40 [6255329.001]
  • [Cites] J Clin Epidemiol. 1989;42(12):1207-13 [2585011.001]
  • [Cites] J Clin Gastroenterol. 1990 Apr;12(2):127-9 [2157745.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1992 May-Jun;1(4):261-8 [1303125.001]
  • [Cites] N Engl J Med. 1995 Feb 16;332(7):413-8 [7824015.001]
  • [Cites] Int J Cancer. 1997 Sep 17;72(6):977-81 [9378561.001]
  • [Cites] Br J Cancer. 1998 Apr;77(7):1045-7 [9569037.001]
  • [Cites] Clin Exp Allergy. 1999 Mar;29(3):342-6 [10202341.001]
  • [Cites] Lancet. 1999 Sep;354 Suppl 2:SII12-5 [10507253.001]
  • [Cites] J Clin Immunol. 2004 Nov;24(6):617-22 [15622446.001]
  • [Cites] Clin Exp Dermatol. 2006 Jan;31(1):89-93 [16309494.001]
  • [Cites] J Pathol. 2006 Jan;208(2):176-86 [16362996.001]
  • [Cites] Int J Dermatol. 2006 Mar;45(3):251-6 [16533224.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1315-21 [16923562.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2382-8 [17332371.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):442-7 [17390376.001]
  • [Cites] Neurology. 2007 Jul 24;69(4):381-8 [17646631.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1561-6 [17684129.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3377-82 [18077789.001]
  • [Cites] BMC Immunol. 2008;9:65 [18990206.001]
  • [Cites] Am J Pathol. 1991 Dec;139(6):1259-65 [1661073.001]
  • [Cites] Clin Exp Allergy. 2000 Nov;30(11):1590-6 [11069568.001]
  • (PMID = 19738032.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA110836; United States / NCI NIH HHS / CA / 1R01CA58839; United States / NCI NIH HHS / CA / 1R03CA110836-01A2; United States / NCI NIH HHS / CA / R03CA110836-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Twin Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IL6 protein, human; 0 / Interleukin-6; 187348-17-0 / Interleukin-12
  • [Other-IDs] NLM/ PMC2774542
  •  go-up   go-down


98. Lynch SM, Mahajan R, Beane Freeman LE, Hoppin JA, Alavanja MC: Cancer incidence among pesticide applicators exposed to butylate in the Agricultural Health Study (AHS). Environ Res; 2009 Oct;109(7):860-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although limited, epidemiologic studies suggest possible associations between butylate use and cancer risk, specifically prostate cancer and non-Hodgkin lymphoma (NHL).
  • We observed a significantly elevated joint effect of prostate cancer family history and high butylate usage across both exposure metrics and both referent groups (low-exposed referent: RR(LD)=2.00, 95% CI=1.07-3.74), and a non-significant, elevated interaction between butylate use and prostate cancer family history, similar to a previous AHS finding.
  • Statistically significant increased risks and exposure-response trends were seen for all lymphohematopoietic cancers (AL) and NHL for both exposure metrics and referent groups (low-exposed referent: AL:RR(LD)=2.27, 95% CI=1.18-4.37; NHL: RR(LD)=3.44, 95% CI=1.29-9.21).
  • Further study is warranted for AL, NHL and prostate cancers.
  • [MeSH-major] Agricultural Workers' Diseases / chemically induced. Lymphoma, Non-Hodgkin / chemically induced. Occupational Exposure / adverse effects. Pesticides / poisoning. Prostatic Neoplasms / chemically induced. Thiocarbamates / poisoning
  • [MeSH-minor] Adult. Cohort Studies. Female. Humans. Iowa / epidemiology. Male. Middle Aged. North Carolina / epidemiology. Prevalence. Prospective Studies. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Farm Health and Safety.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • MedlinePlus Health Information. consumer health - Pesticides.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BUTYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Epidemiol. 2000 Dec;29(6):1014-24 [11101542.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1076:120-8 [17119197.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1155-63 [11700263.001]
  • [Cites] Epidemiology. 2002 Jan;13(1):94-9 [11805592.001]
  • [Cites] Int J Occup Med Environ Health. 2001;14(4):339-47 [11885917.001]
  • [Cites] Ann Occup Hyg. 2002 Mar;46(2):245-60 [12074034.001]
  • [Cites] J Expo Anal Environ Epidemiol. 2002 Sep;12(5):313-8 [12198579.001]
  • [Cites] Int J Cancer. 2003 Apr 20;104(4):458-61 [12584743.001]
  • [Cites] Am J Epidemiol. 2003 May 1;157(9):800-14 [12727674.001]
  • [Cites] Occup Environ Med. 2003 Sep;60(9):634-42 [12937183.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):1197-201 [14871857.001]
  • [Cites] Mutat Res. 1984 Jun;136(3):233-45 [6377060.001]
  • [Cites] JAMA. 1986 Sep 5;256(9):1141-7 [3801091.001]
  • [Cites] Cancer Causes Control. 2000 Jan;11(1):37-47 [10680728.001]
  • [Cites] Cancer Res. 1990 Jun 15;50(12):3610-3 [2340509.001]
  • [Cites] J Urol. 1991 Nov;146(5):1305-7 [1942282.001]
  • [Cites] Occup Med. 1991 Jul-Sep;6(3):335-54 [1835166.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2447-55 [1568215.001]
  • [Cites] Scand J Work Environ Health. 1992 Aug;18(4):209-15 [1411362.001]
  • [Cites] Am J Epidemiol. 1993 Feb 1;137(3):270-80 [8452135.001]
  • [Cites] Prostate. 1995 Nov;27(5):250-7 [7479392.001]
  • [Cites] Environ Health Perspect. 1996 Apr;104(4):362-9 [8732939.001]
  • [Cites] Am J Ind Med. 1997 Feb;31(2):233-42 [9028440.001]
  • [Cites] Occup Environ Med. 1997 Mar;54(3):152-66 [9155776.001]
  • [Cites] Cancer Causes Control. 1997 Jul;8(4):568-74 [9242472.001]
  • [Cites] Ann Epidemiol. 1998 Jan;8(1):64-74 [9465996.001]
  • [Cites] Int J Cancer. 1999 Mar 1;80(5):641-5 [10048959.001]
  • [Cites] Environ Res. 1999 Feb;80(2 Pt 1):172-9 [10092410.001]
  • [Cites] J Occup Environ Med. 1999 Apr;41(4):279-88 [10224594.001]
  • [Cites] Eur J Cancer. 1999 Feb;35(2):272-7 [10448270.001]
  • [Cites] J Occup Environ Hyg. 2005 Mar;2(3):194-201 [15764542.001]
  • [Cites] Asian Pac J Cancer Prev. 2005 Jan-Mar;6(1):33-6 [15780029.001]
  • [Cites] Cancer Causes Control. 2005 Jun;16(5):599-607 [15986116.001]
  • [Cites] Toxicol Appl Pharmacol. 2005 Sep 1;207(2):179-86 [16102569.001]
  • [Cites] Cancer Causes Control. 2005 Dec;16(10):1215-24 [16215872.001]
  • [Cites] Cancer Causes Control. 2006 Oct;17(8):1045-52 [16933055.001]
  • [Cites] Carcinogenesis. 2006 Oct;27(10):2001-7 [16543249.001]
  • [Cites] J Occup Environ Med. 2001 Jul;43(7):641-9 [11464396.001]
  • (PMID = 19615679.001).
  • [ISSN] 1096-0953
  • [Journal-full-title] Environmental research
  • [ISO-abbreviation] Environ. Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010119-12
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pesticides; 0 / Thiocarbamates; 3U78PG73G7 / butylate
  • [Other-IDs] NLM/ NIHMS132787; NLM/ PMC3799990
  •  go-up   go-down


99. Diaz J, Antoine J, Azad N: A case of hypoglycemia, lactic acidosis, and hematologic malignancy. Endocr Pract; 2010 Mar-Apr;16(2):241-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On bone marrow biopsy, he was found to have immature B-cell lymphoma and myelodysplasia.
  • There have been 28 previously reported cases of non-Hodgkin lymphoma-induced lactic acidosis in adult patients (11 with hypoglycemia), which has been associated with a high mortality rate.
  • CONCLUSION: Our case is unique because, to our knowledge, it is the first reported case of immature B-cell lymphoma/leukemia and myelodysplasia with a complex karyotype based on extensive cytogenetic studies in a patient presenting with hypoglycemia, lactic acidosis, and central nervous system involvement by lymphoma.
  • [MeSH-major] Acidosis, Lactic / diagnosis. Hypoglycemia / diagnosis. Lymphoma, B-Cell / diagnosis

  • Genetic Alliance. consumer health - Lactic Acidosis.
  • Genetic Alliance. consumer health - Hypoglycemia.
  • MedlinePlus Health Information. consumer health - Hypoglycemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19833585.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Aksoy S, Harputluoglu H, Kilickap S, Dincer M, Dizdar O, Akdogan B, Ozen H, Erman M, Celik I: Erectile dysfunction in successfully treated lymphoma patients. Support Care Cancer; 2008 Mar;16(3):291-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erectile dysfunction in successfully treated lymphoma patients.
  • BACKGROUND: Information on male potency in lymphoma survivors is insufficient.
  • In this study, we assessed male sexual function and serum gonadotropins in successfully treated lymphoma patients.
  • MATERIALS AND METHODS: Fifty-nine patients treated for Hodgkin's lymphoma (HL) or non-HL (NHL) with chemotherapy +/- radiotherapy were included in the study.
  • Thirty-eight (64.4%) had HL and 21 (35.6%) NHL.
  • Presence of ED and its grade were not different between HL and NHL patients.
  • Clinicians should be aware of this problem in lymphoma survivors and offer these patients adequate treatment options.
  • [MeSH-major] Erectile Dysfunction / epidemiology. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Chi-Square Distribution. Combined Modality Therapy. Gonadotropins / blood. Humans. Male. Middle Aged. Risk Factors. Statistics, Nonparametric. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Erectile Dysfunction.
  • MedlinePlus Health Information. consumer health - Erectile Dysfunction.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2002 Feb;13(2):333 [11886015.001]
  • [Cites] Cancer Treat Rev. 2004 Apr;30(2):173-80 [15023435.001]
  • [Cites] Eur Urol. 1993;23(1):172-6 [8477777.001]
  • [Cites] Urology. 2002 Jun;59(6):803-10 [12031357.001]
  • [Cites] J Clin Oncol. 1986 May;4(5):805-14 [3486256.001]
  • [Cites] Baillieres Best Pract Res Clin Endocrinol Metab. 2000 Sep;14(3):453-71 [11097786.001]
  • [Cites] Fertil Steril. 1985 Jun;43(6):927-30 [3922808.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2253-4 [15169819.001]
  • [Cites] Eur J Cancer. 1991;27(11):1389-92 [1835853.001]
  • [Cites] JAMA. 1981 Apr 3;245(13):1323-8 [7206131.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):979-88 [8487061.001]
  • [Cites] J Assoc Physicians India. 1994 Aug;42(8):604-5 [7868551.001]
  • [Cites] Ann Oncol. 2001 Sep;12(9):1307-11 [11697845.001]
  • [Cites] Urology. 1997 Jun;49(6):822-30 [9187685.001]
  • [Cites] Br J Cancer. 1999 May;80(5-6):801-7 [10360658.001]
  • [Cites] Med Pediatr Oncol. 2000 Jul;35(1):52-63 [10881008.001]
  • [Cites] Int J Impot Res. 2004 Oct;16 Suppl 2:S26-39 [15496854.001]
  • [Cites] Eur Urol. 2005 Jan;47(1):80-5; discussion 85-6 [15582253.001]
  • [Cites] J Urol. 1994 Jan;151(1):54-61 [8254833.001]
  • (PMID = 17661093.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Gonadotropins
  •  go-up   go-down






Advertisement